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We developed statistical methods for evaluating the added value of biomarkers for predicting binary outcomes
when biomarker data has limited availability. In the first project, we considered a cost effective study design
called “two-phase study”, where data on the outcome and established risk predictors was collected for all study
subjects in Phase I while biomarkers were measured only for a judiciously selected subset in Phase II. Using a
logistic regression model to describe the relationship between the binary outcome and risk predictors, we
developed three approaches to estimating the risk distribution and summary measures of predictive accuracy.
We showed that all three estimators were consistent and asymptotically normally distributed, and compared
the efficiency and robustness of the three methods through extensive simulation studies and application to an
ongoing biomarker study of Gestational Diabetes. We also developed a novel sampling strategy for selecting
Phase II subjects towards improved efficiency for estimating measures of predictive accuracy. In the second
project, we developed a statistical method for alleviating the challenge of lack of independent data to validate
biomarkers for prediction, focusing on model calibration. When a well-calibrated model with only standard
predictors exists, we proposed to calibrate the new model to the existing model at the stage of model
development. With data collected under a case-control study design, we developed a novel constrained
maximum likelihood approach to fitting logistic regression models that brought this idea to fruition. We
developed large sample theory for this method, and performed extensive simulation studies to assess the
impact of constraints on the odds ratio parameter estimates. We applied our method to analyze a case-control
study of breast cancer nested within the Breast Cancer Detection and Demonstration Project to evaluate the
added value of mammographic density for predicting the 5-year risk of breast cancer. In the third project, we
extended the statistical method developed in the second project to accommodate the cross-sectional study
design. By simulation studies and the analysis of Gestational Diabetes, we demonstrated that our method
ensured that the model was well calibrated.
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ABSTRACT
SEMIPARAMETRIC APPROACHES TO DEVELOPING MODELS FOR PREDICTING BINARY
OUTCOMES THROUGH DATA AND INFORMATION INTEGRATION
Xinglei Chai
Jinbo Chen
We developed statistical methods for evaluating the added value of biomarkers for predicting bi-
nary outcomes when biomarker data has limited availability. In the first project, we considered a
cost effective study design called two-phase study, where data on the outcome and established
risk predictors was collected for all study subjects in Phase I while biomarkers were measured
only for a judiciously selected subset in Phase II. Using a logistic regression model to describe
the relationship between the binary outcome and risk predictors, we developed three approaches
to estimating the risk distribution and summary measures of predictive accuracy. We showed that
all three estimators were consistent and asymptotically normally distributed, and compared the effi-
ciency and robustness of the three methods through extensive simulation studies and application to
an ongoing biomarker study of Gestational Diabetes. We also developed a novel sampling strategy
for selecting Phase II subjects towards improved efficiency for estimating measures of predictive
accuracy. In the second project, we developed a statistical method for alleviating the challenge
of lack of independent data to validate biomarkers for prediction, focusing on model calibration.
When a well-calibrated model with only standard predictors exists, we proposed to calibrate the
new model to the existing model at the stage of model development. With data collected under
a case-control study design, we developed a novel constrained maximum likelihood approach to
fitting logistic regression models that brought this idea to fruition. We developed large sample the-
ory for this method, and performed extensive simulation studies to assess the impact of constraints
on the odds ratio parameter estimates. We applied our method to analyze a case-control study of
breast cancer nested within the Breast Cancer Detection and Demonstration Project to evaluate
the added value of mammographic density for predicting the 5-year risk of breast cancer. In the
third project, we extended the statistical method developed in the second project to accommodate
the cross-sectional study design. By simulation studies and the analysis of Gestational Diabetes,
we demonstrated that our method ensured that the model was well calibrated.
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CHAPTER 1
INTRODUCTION
1
1.1.
Accurate risk prediction is central to precision medicine and precision disease prevention. Modern
technology has enabled widespead efforts of biomarker discovery, promising great possibilities of
improving risk prediction for human diseases. For putative biomarkers, it is of ultmost interest to
evaluate their added values for prediction. But this is a challenging task. The model development
requires data for disease status, biomarkers, as well as established risk predictors from a sample
that is of sufficiently large size to allow stable model fitting. In practice, initial investigation efforts
most often afford collection of data only from a small number of subjects.
The two-phase study design, which was firstly introduced by Neyman (1938), is commonly con-
ducted in medical research due to their economy and efficiency. In this design, data is collected in
two phases (Neyman, 1938; White, 1982). In Phase I, data on the outcome and conventional risk
predictors is collected for all study subjects. In Phase II, biomarkers are measured for a judiciously
selected subset. In the study of gestational diabetes mellitus (GDM), a case-control study nested
in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Fetal Growth StudySingletons cohort (Zhu et al., 2016), data can be seen as being collected in
two phases. In this prospective study cohort (Phase I) , data on conventional predictors such as
age, race, body mass index, and family history was fully collected for 2,799 women. Blood samples
were collected for the full cohort prior to the GDM screening. To study biomarkers in relation to
the risk of GDM, a nested case-control subsample (Phase II) was assembled, where two controls
were matched to each of the 107 cases on ethnicity, age within 2 years, and gestational weeks.
Biomarkers were measured only for this case-control subset. It was of interest to develop a model
for predicting the risk of GDM using both conventional risk predictors and new biomarkers. How-
ever, such two-phase studies induce incomplete data and pose significant statistical challenges
both in developing a comprehensive risk model and its validation. It is well known that naive anal-
ysis using only Phase II data with the sampling procedure ignored leads to biased estimation and
decreased power.
In Chapter 2, we develop statistical methods for estimating the absolute risk for a binary outcome
and several summary measures of prediction accuracy with two-phase data. Specifically, we con-
sider estimation of the receiver operating characteristic (ROC) curve and the area under the ROC
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curve (AUC), which are routinely reported to gauge the discriminatory capacity of a prediction
model. We also consider the proportion of cases followed (PCF; Pfeiffer and Gail, 2011) which
is the probability that a case is included in a high-risk group, and the proportion needed to follow
(PNF; Pfeiffer and Gail, 2011), which is the proportion of high-risk subjects that contain a speci-
fied proportion of cases. PCF and PNF measure the concentration of risk in the population and
can be used to quantify the usefulness of a model in a risk-based screening program. PCF and
PNF are of particular interest to our GDM study example, because the ultimate goal is to develop
a model to help screen high-risk women upon validation. The current literature for analyzing two-
phase data has been mainly focused on the estimation of association parameters that describe the
relationship between an outcome variable and predictors. The available methods that account for
biased sampling of a two-phase study largely fell into four class: semiparametric maximum likeli-
hood methods (ML; Breslow and Holubkov, 1997; Scott and Wild, 1997; Wang and Zhou, 2010),
pseudo-likelihood (PL; Breslow and Cain, 1988; Breslow and Zhao, 1988) or estimated likelihood
(Carroll and Wand, 1991; Pepe and Fleming, 1991) methods, weighted likelihood methods (WL;
Flanders and Greenland, 1991; Ibrahim, 1990; Lipsitz, Ibrahim, and Zhao, 1999; Robins, Rotnitzky,
and Zhao, 1994), and methods based on modifying likelihood score functions for the complete data
(Chatterjee, Chen, and Breslow, 2003; Reilly and Pepe, 1995). Most of these methods have been
synthesized and further extended in the seminal paper (Lawless, Kalbfleisch, and Wild, 1999). Cur-
rently, there is a paucity of procedures that can be applied to the two-phase setting for estimating
measures of accuracy for predicting binary outcomes. Existing methods were not able to fully ac-
commodate stratified sampling of Phase II subjects (Huang, 2016; Huang and Pepe, 2010), limited
to the estimation of AUC (Huang, 2016; Pepe, Fan, and Seymour, 2013), or focused on the failure
time data (Cai and Zheng, 2012; Liu, Cai, and Zheng, 2012). To our best knowledge, no meth-
ods are yet available for estimating the key accuracy measures PCF and PNF for our GDM study
example.
We consider the general two-phase sampling scheme where the probability that a subject is se-
lected into Phase II depends only on his/her own characteristics, and adopt logistic regression
models for prediction. The estimation of predictive accuracy measure requires estimation of the
risk distribution, which is a function of the odds ratio (OR) parameters and the predictor distribution.
For estimating the OR parameters with two-phase data, the semiparametric ML method (Lawless,
Kalbfleisch, and Wild, 1999; Scott and Wild, 1997), the PL method (Breslow and Cain, 1988; Bres-
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low and Zhao, 1988), and the WL method (Flanders and Greenland, 1991; Robins, Rotnitzky, and
Zhao, 1994) have been widely used in practice. Each of them has its own pros and cons, and they
have been implemented in widely used R packages. Therefore, we propose three corresponding
methods for estimating risk distribution and predictive accuracy measures.
In this chapter, we also explore efficient sampling strategies for selecting Phase II subjects in order
to improve statistical efficiency for estimating predictive accuracy measures. It has been shown
that selection stratified by case-control status alone or together with a small number of discrete
Phase I variables can lead to a more informative Phase II sample than that obtained via simple
random sampling (Breslow and Cain, 1988; Breslow and Chatterjee, 1999). The latter selects
similar numbers of Phase II subjects across strata, and is particularly attractive for increasing the
efficiency for estimating OR parameters when the outcome is rare and some values of Phase I
variables occur infrequently. This “balanced” design requires categorization of Phase I predictors,
but there is no guidance on how to do so when multiple phase I predictors are available. One
may choose to stratify by only a single Phase I predictor, or by coarse categories based on multiple
predictors defined in such a way that a sufficient number of Phase I cases and controls are available
for selection within each stratum. We propose to sample Phase II subjects based on a preliminary
prediction model that includes only Phase I variables as predictors.
1.2.
To assess the value of biomarkers that adds to the established risk predictors to achieve improved
prediction, it is important that the model is well calibrated since good calibration is essential in order
to inform patients about their risks and make risk-based decision. However, the subsequent model
validation is challenging because it requires data to be collected from sources independent of those
for model development and these independent datasets most ofter are not readily available. Even
if data for the outcome and standard risk predictors may well be available from existing studies
or can be easily obtained, it is usually much more challenging to obtain biomarker data. Lack of
independent validation data has been an obvious factor that hinders translation of biomarkers to
clinics. For example, the breast cancer risk assessment tool (BCRAT), which was developed using
data from a case-control study of breast cancer that was nested in the Breast Cancer Detection and
Demonstration Project (BCDDP), was calibrated to the composite breast cancer rates reported in
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the Surveillance, Epidemiology, End Results program, making it a useful tool for projecting individ-
ualized risk for the U.S. Caucasian women. Percent mammographic density was incorporated as a
strong risk predictor into the BCRAT (Chen et al., 2006), and led to an increase in the area under
the ROC curve that is comparable to that by incorporation of breast cancer risk SNPs identified
to date. However, validation studies has yet to be conducted after more than 10 years since this
updated model was published. Even if the data for validation is fully available, the sample size may
limit the power for detecting lack of calibration. Recent work shows that greater than 10,000 sub-
jects were required in order to detect meaningful differences between the predicted and observed
risks in the upper tail of the risk distribution (Chatterjee et al., 2016).
Fortunately, data from multiple sources becomes more and more available that can be exploited
to enhance model development and validation, which may compensate the scarce of biomarker
data. The incidence rates for common diseases in the U.S. are publically available. Population
level data for standard risk predictors is frequently available from national and international efforts
or existing cohort studies. For example, the BCRAT risk predictors are fully represented in the
National Health Interview Survey (NHIS III). The relationship between the outcome and standard
risk predictors may have been assessed in multiple studies, or a risk prediction model that uses only
standard predictors may have been developed and validated extensively. Data may be available
for characterizing the relationship between biomarkers and standard risk predictors. Aiming to
exploit these existing resources for model development and validation, we develop novel statistical
methods for predicting the risk of a binary outcome using the logistic regression model.
In Chapter 3, we consider a scenario where a well calibrated model based on standard predictors
exists, and focus on a central task of incorporating new risk predictors into the existing model, which
henceforth is referred to as the “base model”. We consider a case-control study design, which is
also a cost-effective option for recruiting subjects and collecting data on disease status, biomarkers
and established risk predictors. The standard method for analysis would be to fit a prospective
logistic regression model that includes an offset term to adjust for case-control sampling. Here, we
develop a novel constrained maximum likelihood method, which has four features that distinguish
it from the standard method. First, our method ensures that the new model calibrates similarly
as the base model, in the sense that the predicted risk by the new model in the population strata
defined by standard predictors is comparable to that by the base model. Because the base model
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is well calibrated, such agreement between the two models lends support to the good calibration of
the new model in the absence of independent validation data. A similar idea of indirect calibration
was successfully applied for updating the BCRAT by incorporating percent mammographic density
(Chen et al., 2006). Second, our method explicitly recognizes that the underlying population from
which the case-control sample was assembled may not have the same distribution of standard risk
predictors as the target population for prediction. In BCDDP, the participants were recruited from
women who volunteered to undergo mammographic screening and they turned out to have higher
average risk of breast cancer than the general U.S. Caucasian women. The distribution of BCRAT
risk predictors in the BCDDP also differs from that estimated from the National Health Interview
Survey (NHIS), where the latter better represents the general Caucasian woman population. Third,
our method accommodates the known distribution of standard risk predictors in the target popula-
tion, while relying on the case-control data for information on biomarkers. Fouth, our method more
readily accommodates smaller sample sizes because of its high statistical efficiency.
Our method is based on maximizing the likelihood function under the constraints translated from
the base model and external information on standard risk predictors. Using a parametric regres-
sion model to describe the relationship between the biomarker and standard risk predictors, we
apply the Lagrange multiplier approach to deriving the profile likelihood for the Euclidean parame-
ters. Constrained maximum likelihood methods have recently been developed to increase statis-
tical efficiency for estimating odds ratio association parameters by exploiting external information
through constraints (Chatterjee et al., 2016; Qin et al., 2015). Putting into the current context,
Qin et al. (2015) exploited known outcome prevalence in strata defined by standard predictors to
increase statistical efficiency, where the underlying population for the case-control sample shares
the same risk and predictor distributions that define the stratum-specific prevalences. Chatterjee
et al. (2016) exploited a known regression relationship between the outcome and standard pre-
dictors to increase statistical efficiency, when the joint distribution for both standard predictors and
biomarkers is known externally. Our method differs in important ways: it exploits stratum-specific
prevalence similarly as Qin et al. (2015), but accommodates known distribution of standard predic-
tors for the target population of prediction while requiring information on biomarkers only from the
case-control data. These differences lead to important practical implications: the model developed
using our method calibrates to the target population, where the calibration is defined by the agree-
ment between the predicted and estimated risks in discrete population strata as commonly done
6
for assessing goodness-of-fit of regression models. These differences also call for new theoretical
development for statistical inference.
1.3.
In Chapter 4, we extend the statistical method developed in Chapter 3 to accommodate the cross-
sectional study design, which often can not be treated as a random sample selected from the
target population. We consider the same scenario where a well calibrated model based on stan-
dard predictors exists, and the goal is to incorporate the new risk predictors into the existing model.
We assume that data on the outcome and all predictors is available from a cross-sectional sam-
ple. After re-deriving the likelihood function, we propose a similar constrained maximum likelihood
method, which guarantees that the new model calibrates similarly as the existing model, allows the
distribution of standard risk predictors in the sample to be different from that in the target popula-
tion of prediction, and relies on the data to infer the relationship between biomarkers and standard
predictors. This work is motivated by the study of Gestational Diabetes Mellitus as described in
Chapter 2 (Zhu et al., 2016). The Phase I sample in the study can be seen as a prospective cohort
study, where data on the outcome and predictors including age, race, BMI and family history was
measured for all study subjects. The distribution of age, race and BMI is externally available in the
National Vital Statistics Report (NVSR) from Centers for Disease Control and Prevention (CDC),
which turns out to be quite different from that in the data. Given that the information of the relation-
ship between family history and these predictors is limited or unknown, we formulate the problem
into our constrained MLE approach framework by treating family history as the “new” predictor. The
goal is to develop a logistic regression model with all four predictors included and the model is cal-
ibrated to an existing logistic regression model based on age, race and BMI with ORs reported in
the previous literature (Berkowitz et al., 1992; Solomon et al., 1997). We provide simulation results
to assess the performance of our method.
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CHAPTER 2
DESIGN AND ANALYSES OF TWO-PHASE STUDIES FOR PREDICTING BINARY
OUTCOMES
8
2.1. Introduction
This work was motivated by statistical challenges arising from the development of a model for pre-
dicting the risk of gestational diabetes mellitus (GDM) using a case-control study nested in the
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal
Growth StudySingletons cohort. In this prospective study cohort (Zhu et al., 2016), data on con-
ventional predictors such as age, race, body mass index, and family history was fully collected for
2,799 women. Blood samples were collected for the full cohort prior to the GDM screening. To
study biomarkers in relation to the risk of GDM, a nested case-control subsample was assembled,
where two controls were matched to each of the 107 cases on ethnicity, age within 2 years, and
gestational weeks. Biomarkers were measured only for this case-control subset. It was of interest
to develop a model for predicting the risk of GDM using both conventional risk predictors and new
biomarkers. The data can be seen as being collected in two phases (Neyman, 1938; White, 1982).
In Phase I, data on the outcome and conventional risk predictors was collected for all study sub-
jects. In Phase II, biomarkers were measured from the blood only for a judiciously selected subset.
Such two-phase studies, while commonly conducted in medical research, induce incomplete data
and pose significant statistical challenges both in developing a comprehensive risk model and its
validation. It is well known that naive analysis using only Phase II data with the sampling procedure
ignored leads to biased estimation and decreased power.
In this work, we develop statistical methods for estimating the absolute risk for a binary outcome and
several summary measures of prediction accuracy with two-phase data. Specifically, we consider
estimation of the receiver operating characteristic (ROC) curve and the area under the ROC curve
(AUC), which are routinely reported to gauge the discriminatory capacity of a prediction model. We
also consider the proportion of cases followed (PCF; Pfeiffer and Gail, 2011) which is the probability
that a case is included in a high-risk group, and the proportion needed to follow (PNF; Pfeiffer and
Gail, 2011), which is the proportion of high-risk subjects that contain a specified proportion of cases.
PCF and PNF measure the concentration of risk in the population and can be used to quantify the
usefulness of a model in a risk-based screening program. PCF and PNF are of particular interest
to our GDM study example, because the ultimate goal is to develop a model to help screen high-
risk women upon validation. The current literature for analyzing two-phase data has been mainly
focused on the estimation of association parameters that describe the relationship between an
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outcome variable and predictors. The available methods that account for biased sampling of a two-
phase study largely fell into four class: semiparametric maximum likelihood methods (ML; Breslow
and Holubkov, 1997; Scott and Wild, 1997; Wang and Zhou, 2010), pseudo-likelihood (PL; Breslow
and Cain, 1988; Breslow and Zhao, 1988) or estimated likelihood (Carroll and Wand, 1991; Pepe
and Fleming, 1991) methods, weighted likelihood methods (WL; Flanders and Greenland, 1991;
Ibrahim, 1990; Lipsitz, Ibrahim, and Zhao, 1999; Robins, Rotnitzky, and Zhao, 1994), and meth-
ods based on modifying likelihood score functions for the complete data (Chatterjee, Chen, and
Breslow, 2003; Reilly and Pepe, 1995). Most of these methods have been synthesized and further
extended in the seminal paper (Lawless, Kalbfleisch, and Wild, 1999). Currently, there is a paucity
of procedures that can be applied to the two-phase setting for estimating measures of accuracy
for predicting binary outcomes. Existing methods were not able to fully accommodate stratified
sampling of Phase II subjects (Huang, 2016; Huang and Pepe, 2010), limited to the estimation of
AUC (Huang, 2016; Pepe, Fan, and Seymour, 2013), or focused on the failure time data (Cai and
Zheng, 2012; Liu, Cai, and Zheng, 2012). To our best knowledge, no methods are yet available for
estimating the key accuracy measures PCF and PNF for our GDM study example.
We consider the general two-phase sampling scheme where the probability that a subject is se-
lected into Phase II depends only on his/her own characteristics, and adopt logistic regression
models for prediction. The estimation of predictive accuracy measure requires estimation of the
risk distribution, which is a function of the odds ratio (OR) parameters and the predictor distribution.
For estimating the OR parameters with two-phase data, the semiparametric ML method (Lawless,
Kalbfleisch, and Wild, 1999; Scott and Wild, 1997), the PL method (Breslow and Cain, 1988; Bres-
low and Zhao, 1988), and the WL method (Flanders and Greenland, 1991; Robins, Rotnitzky, and
Zhao, 1994) have been widely used in practice. Each of them has its own pros and cons, and they
have been implemented in widely used R packages. Therefore, we propose three corresponding
methods for estimating risk distribution and predictive accuracy measures.
In this work, we also explore efficient sampling strategies for selecting Phase II subjects in order
to improve statistical efficiency for estimating predictive accuracy measures. It has been shown
that selection stratified by case-control status alone or together with a small number of discrete
Phase I variables can lead to a more informative Phase II sample than that obtained via simple
random sampling (Breslow and Cain, 1988; Breslow and Chatterjee, 1999). The latter selects
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similar numbers of Phase II subjects across strata, and is particularly attractive for increasing the
efficiency for estimating OR parameters when the outcome is rare and some values of Phase I
variables occur infrequently. This “balanced” design requires categorization of Phase I predictors,
but there is no guidance on how to do so when multiple phase I predictors are available. One
may choose to stratify by only a single Phase I predictor, or by coarse categories based on multiple
predictors defined in such a way that a sufficient number of Phase I cases and controls are available
for selection within each stratum. We propose to sample Phase II subjects based on a preliminary
prediction model that includes only Phase I variables as predictors.
The rest of the chapter is organized as follows. In Section 2.2, we develop three methods for esti-
mating risk distribution and predictive accuracy measures under the two-phase study design, and
provide an inference procedure for each method. In Section 2.3, we conduct extensive simulation
studies to evaluate the finite sample performance of the proposed methods under different sampling
strategies. In Section 2.4, we apply our method to analyze the example GDM study to develop a
preliminary prediction model. We conclude with some remarks in Section 2.5.
2.2. The Model, Estimation, and Inference Procedure
2.2.1. Model
We consider a prospective two-phase study design where Phase I is a representative cohort of size
N drawn from a population of interest. Data on the binary outcome Y , with Y = 1 indicating cases
and Y = 0 indicating controls, and sampling stratum S, is available for all N subjects. Stratified by
Y and S, a subset of subjects is randomly selected into Phase II for measuring predictors (X,Z).
Let Nys and nys, y = 0, 1 and s = 1, 2, ..., S, denote the number of Phase I and Phase II subjects
with Y = y in the stratum S = s, respectively. We adopt a logistic regression model to describe the
relationship between Y and (X,Z):
p(Y = 1|S = s,x, z) ≡ p1(x, z;θ) = exp(α+ β
Tx + γT z)
1 + exp(α+ βTx + γT z)
, (2.1)
where θ denotes (α,β,γ). Here, we assume that the probability of Y depends on stratum S only
through predictors X. The requirement that S is not associated with Y given (X,Z), p(Y = 1|S =
s,x, z) = p1(x, z;θ), is naturally satisfied when S is the same as, a discretized version of, or a
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surrogate of a subset of predictors X. Let F denote the cumulative distribution function (CDF) for
(X,Z). We are interested in estimating the distribution of risk p1(x, z;θ) and the three predictive
accuracy measures, AUC, the PCF at risk quantile q (0 < q < 1), and the PNF for capturing
percentage p cases (0 < p < 1), which can all be expressed as the risk distribution and CDF F as
follows:
AUC(θ, F ) =
∫
TPRν(θ, F )d{FPRν(θ, F )},
where TPRν(θ, F ) and FPRν(θ, F ) are the true and false positive rates at risk cutoff ν, respectively:
TPRν = Pr{p1(x, z;θ) > ν|Y = 1} =
∫
I{p1(x, z;θ) > ν}p1(x, z;θ)dF (x, z)∫
p1(x, z;θ)dF (x, z)
,
FPRν = Pr{p1(x, z;θ) > ν|Y = 0} =
∫
I{p1(x, z;θ) > ν}{1− p1(x, z;θ)}dF (x, z)∫ {1− p1(x, z;θ)}dF (x, z) .
Define the qth upper quantile of the risk distribution ξq by equation q = Pr{p1(x, z;θ) > ξq} =∫
I{p1(x, z;θ) > ξq}dF (x, z), which is also a function of parameters (θ, F ). Then PCFq(θ, F ) has
the same expression as TPR(θ, F ), except that the risk cutoff equals ξq:
PCFq(θ, F ) = Pr{p1(x, z;θ) > ξq|Y = 1} =
∫
I{p1(x, z;θ) > ξq}p1(x, z;θ)dF (x, z)∫
p1(x, z;θ)dF (x, z)
.
PNFp(θ, F ) is formally defined as the probability that the predicted risk is higher than the pth quantile
of the risk distribution for cases:
PNFp(θ, F ) = Pr{p1(x, z;θ) > ξp} =
∫
I{p1(x, z;θ) > ξp}dF (x, z),
where ξp is defined by equation p = PCFp(θ, F ).
The estimates of these three measures can be obtained upon plugging in the estimates for θ and
F . If data for all predictors were collected for every subject in the cohort, the maximum likelihood
estimate for θ, θˆ, can be obtained by standard logistic regression, and the CDF of the predictors F
can be estimated empirically as
Fˆ (x, z) =
1
N
N∑
k=1
I{Xk ≤ x,Zk ≤ z}.
Plug-in estimators AUC(θˆ, Fˆ ), PCFq(θˆ, Fˆ ), and PNFp(θˆ, Fˆ ) can be obtained accordingly.
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2.2.2. Estimation and Sampling Strategies under the Two-Phase Design
Under the two-phase study design, (X,Z) is selectively measured based on Y and stratum infor-
mation S collected in Phase I. Therefore, fitting model (2.1) to Phase II data alone will yield a biased
estimate of OR parameters θ and subsequent predictive accuracy measures. Below, we describe
three estimators for θ as mentioned in introduction, propose three corresponding estimators for the
CDF F (x, z), and subsequently propose three corresponding methods for estimating the predic-
tive accuracy measures. We derive the large sample distributions of the three sets of estimators.
These methods are expected to have different statistical efficiencies and involve different levels of
computational complexity.
Semiparametric Maximum Likelihood Method
Let PI and PII denote subjects in Phase I and Phase II, respectively, and Rysk be the indicator of
whether or not the kth subject with outcome Y = y from stratum s in Phase I sample is included
in Phase II (Rysk = 1: yes; Rysk = 0: no). Let ηxzs = p(X = x,Z = z|S = s) denote the stratum-
specific empirical distribution of predictors (X,Z) and py(x, z;θ) denote p(Y = y|x, z;θ). The MLE
of θ, proposed by Scott and Wild (1997), is obtained by maximizing the empirical log-likelihood
function of both Phase I and Phase II data, which can be written as
lML = log
∏
PI
p(Y, S)
∏
PII
p(X,Z|Y, S)
=
1∑
y=0
S∑
s=1
Nys∑
k=1
[
(1−Rysk) log
∫ ∫
py(x, z;θ)ηxzsdxdz
]
+
1∑
y=0
S∑
s=1
Nys∑
k=1
[
Rysk
{
log py(xysk, zysk;θ) + log ηxyskzysks
}]
.
Let
∑
(x,z)⊂(y,s) denote summation over predictors of all Phase II individuals with Y = y in stratum
s. Define new variables µys which has a dimension equal to twice the number of Phase I sampling
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strata:
µys =
nys − γys
Nys − γys
with γys = nys −
∑
(x,z)⊂(1,s)
p?y(x, z;θ, s)−
∑
(x,z)⊂(0,s)
p?y(x, z;θ, s), (2.2)
where
p?y(x, z;θ, s) =
µyspy(x, z;θ)∑
y µyspy(x, z;θ)
. (2.3)
By maximizing the likelihood over η with OR parameters θ fixed, an expression of ηxzs as a function
of θ, ηxzs(θ), was obtained as
ηˆxzs(θ) =
n+xzs
N+s
∑
y µyspy(x, z;θ)
, (2.4)
Plugging expression (2.4) into the log likelihood function lML leads to the profile likelihood function
for θ, which, upon maximization, yields the MLE of θ, θˆML. It turns out that θˆML can be obtained
by iteratively fitting the “pseudo-model” p?(x, z;θ, s), using software for standard logistic regression
analysis that includes an offset term logµ1s − logµ0s. This is because the pseudo-model (2.3) can
be equivalently written as
log
p?1(x, z;θ, s)
p?0(x, z;θ, s)
= logµ1s − logµ0s + log p1(x, z;θ)
p0(x, z;θ)
.
The µys values are updated during each iteration. Beginning with γ
(0)
ys = 0, i.e., µ
(0)
ys =
nys
Nys
, an
initial estimate of θ, θˆ
(1)
, is obtained via standard logistic regression analysis with an offset term
log(n1s/n0s)− log(N1s/N0s) using only Phase II subjects. γys is then updated by plugging θˆ(1) into
formula (3). The process continues until convergence to obtain θˆML.
To estimate the CDF F (x, z) that is needed for the estimation of AUC, PCF, and PNF, the MLE of the
empirical distribution ηxzs(θ) is obtained by plugging in equation (2.4) θˆML and the corresponding
µˆys. The MLE of the stratum membership, p(S = s), is simply obtained as (N0s+N1s)/N . Therefore,
we estimate F (x, z) as
FˆML(θˆ) = pˆ(X ≤ x,Z ≤ z) =
∑
s
pˆ(S = s)×
 ∑
(x,z):X≤x,Z≤z
ηˆxzs(θˆML)
 .
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Here we make it explicit that FˆML depends on θˆML.
With θˆ and FˆML obtained, the semiparametric maximum likelihood estimate of the risk distribution
R(r) = Pr{p1(x, z;θ) ≤ r} are now obtained as
Rˆr(θˆML, FˆML) =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) ≤ r}
N
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
.
Below, we refer to the ML estimates of PCFq, PNFp, and AUC correspondingly as PCFq(θˆML, FˆML),
PNFp(θˆML, FˆML), and AUC(θˆML, FˆML). The expression of PCFq(θˆML, FˆML) is given below, and
those of the other two are provided in the Appendices:
P̂CFq(θˆML, FˆML) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)

−1
×
=

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ξq}p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
 ,
where ξq is estimated from equation
q =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ξq}
N
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
.
We derive the large sample distributions of PCFq(θˆML, FˆML), PNFp(θˆML, FˆML), and AUC(θˆML,
FˆML) using the influence function approach. Let TˆML ≡ T{θˆML, FˆML(θˆML)} be a generic term for
any of these three estimators and T ≡ T (θ, F ) be the corresponding true value. We derive a large
sample approximation in the form of
√
N(TˆML − T ) =
√
N
{
1
N
N∑
k=1
HMLTk
}
+ op(1),
where HTk, k = 1, ..., N , the influence function contributed by the kth subject, are independent
and identically distributed with mean 0 and variance σ2. Then,
√
N(TˆML − T ) is asymptotically
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normally distributed with mean 0 and variance σ2 by the central limit theorem. Note that θˆML can
be approximated by an asymptotically linear form, a
√
N(θˆML− θ) =
√
N
{
1
N
∑N
k=1H
ML
θk
}
+ op(1)
(Scott and Wild, 1997), where the influence function HMLθk is provided in Appendices. By applying
the standard Taylor series expansion and Delta method for statistical functionals, we obtain the
asymptotic linear approximation of T{θ, FˆML(θ)},
√
N
[
T{θ, FˆML(θ)} − T (θ, F )
]
=
√
N
{
1
N
N∑
k=1
ϕMLF (Xk,Zk)
}
+ op(1).
Then HMLTk can be accordingly calculated as
HMLTk =
{
∂T
∂θ
|F=FˆML(θˆML) +
∂T
∂FˆML(θ)
∂FˆML(θ)
∂θ
}
HMLθk + ϕ
ML
F (X,Z).
The detailed derivations are provided in Appendices. The variance of HMLTk , σ
2, can be estimated
as the empirical variance of HMLTk , and all partial derivatives involved can be estimated numerically.
Pseudo-Likelihood (PL) Method
The PL approach to estimating θ (Breslow and Cain, 1988; Breslow and Zhao, 1988) is actually the
result from the first step of the iterative process in the ML approach above, θˆ
(1)
. In other words, the
PL estimate of θ, θˆPL, is obtained by maximizing a pseudo-likelihood based on the pseudo-model
defined in model (2.3) over Phase II subjects, but with µys replaced by nys/Nys:
S?PL =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
∂ log p?y(xysk, zysk;θ, s)
∂θ
= 0.
Note that nys/Nys in the large sample converges to piys ≡ p(Rysk = 1|Y = y, S = s), the stratum-
specific probability of being selected into Phase II sample under variable probability sampling (VPS)
(Lawless, Kalbfleisch, and Wild, 1999), where units are considered independent and sequentially
inspected until a total number of nys subjects are selected from each stratum (Y = y, S = s). Let pˆis
denote the vector of sampling probabilities in stratum s for both cases and controls, (pˆiys, y = 0, 1),
and pˆi = {pˆis, s = 1, 2, . . . , S}. For the estimation of F (x, z), motivated by the expression (2.4) and
similarity between the PL and ML methods for estimating θ, we propose a novel pseudo-likelihood
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type estimator of p(x, z|s) as
δˆxzs(θˆPL, pˆis) =
n+xzs
N+s
∑
y nysN
−1
ys py(x, z;θ)
.
With the stratum proportion still estimated as pˆ(S = s) = (N0s +N1s)/N as in the ML method, we
obtain a PL estimate of F (x, z), which depends on the estimated parameters θˆPL and pˆis:
FˆPL(θˆPL, pˆi) =
∑
s
pˆ(S = s)×
 ∑
(x,z):X≤x,Z≤z
δˆxzs(θˆPL, pˆis)
 .
The corresponding PL estimates of the risk distribution R(r), PCFq, PNFp, and AUC are respec-
tively denoted as Rr(θˆPL, FˆPL), PCFq(θˆPL, FˆPL), PNFp(θˆPL, FˆPL), and AUC(θˆPL, FˆPL). The ex-
pressions are similar to those under the ML approach with details provided in Appendices. The
inference procedures are similar to those of the ML method, except that the variability from estimat-
ing the sampling probabilities, pˆi, needs to be taken into account in addition to that due to θˆPL and
FˆPL. The details are provided in Appendices.
Weighted Likelihood (WL) Method
The WL approach analyzes only Phase II subjects but corrects the biased sampling by weighting
the contribution of each subject to the standard likelihood function by the inverse of the subject’s
sampling probability. The corresponding estimate for θ, θˆWL, is the solution to the weighted likeli-
hood score function, defined as
SWL =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
pˆiys
∂ log py(xysk, zysk;θ)
∂θ
= 0.
To estimate the CDF F (x, z), we similarly propose a weighted empirical likelihood estimator as
FˆWL(pˆi) =
1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
RyskI{Xysk ≤ x,Zysk ≤ z}
pˆiys
.
The weighted likelihood estimate of risk distribution R(r) can then be obtained as
Rˆr(θˆWL, FˆWL) =
1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
pˆiys
I{p1(xysk, zysk; θˆWL) ≤ r}.
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We refer to the WL estimates of PCFq, PNFp, and AUC correspondingly as PCFq(θˆWL,FˆWL),
PNFp(θˆWL, FˆWL), and AUC(θˆWL, FˆWL). The expression for PCFq(θˆWL, FˆWL) is given as
P̂CFq(θˆWL, FˆWL) =
∑1
y=0
∑S
s=1
∑Nys
k=1Ryskpˆi
−1
ys I{p1(xysk, zysk; θˆWL) > ξq}p1(xysk, zysk; θˆWL)∑1
y=0
∑S
s=1
∑Nys
k=1Ryskpˆi
−1
ys p1(xysk, zysk; θˆWL)
,
where ξq is estimated from equation
q =
1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys I{p1(xysk, zysk; θˆWL) > ξq}.
Those of the estimates for PNFp(θˆWL, FˆWL) and AUC(θˆWL, FˆWL), together with the large sample
distributions, are provided in Appendices.
An Extended Balanced (E-balanced) Design
An important consideration in designing two-phase studies is to select more informative Phase II
subjects. In a two-phase study that collects additional confounding variables for studying the effect
of a rare exposure, a “balanced” design (Breslow and Cain, 1988), which samples roughly equal
numbers of subjects from strata defined by case-control status and the rare exposure, was shown
to have higher efficiency than sampling equal numbers of cases and controls. The efficiency of this
balanced design is often comparable to that of the optimal design, where the latter is largely infeasi-
ble as it depends on unknown parameters. In addition, it is not clear how to form sampling strata in
the presence of multiple Phase I variables. To increase the efficiency for estimating predictive accu-
racy measures, a desirable strategy would select more informative Phase II subjects to increase the
efficiency of estimating not only the OR parameters, but also the risk predictor distribution. For the
latter, we expect that a strategy that oversamples extreme values of risk predictors would be use-
ful. Therefore, considering that the relationship between standard risk predictors and the outcome
variable has been studied in external studies, we propose to extend the balanced design (Breslow
and Cain, 1988) by incorporating this existing knowledge. Specifically, we propose to stratify Phase
I subjects by the “preliminary” risk predicted by the standard predictors, e.g., based on a logistic
regression model available from an external source. Subjects with extreme preliminary risks are
over-sampled, and within each stratum the number of cases and controls are similar. We call this
design “the E-balanced design”. It naturally accommodates multiple Phase I variables through the
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risk distribution jointly determined by them. Intuitively, this design may have efficiency advantage
for estimating predictive accuracy measures because the “extreme” value of the multiple predictors
is more appropriately defined in terms of classifying subjects based on their risk of developing the
disease. Results from Simulation Studies described below indicated the high efficiency of this de-
sign, and that the efficiency improvement owed to a large extent to improved estimates of the risk
predictor distribution and to a smaller extent to improved estimates of the OR parameters.
2.3. Simulation Studies
We conducted extensive simulation studies to evaluate the finite sample performance of our pro-
posed methods for estimating risk distribution and predictive accuracy measures and to compare
the efficiency of our proposed E-balanced sampling design with the case-control and balanced sam-
pling designs. For the latter, we chose to stratify by one Phase I variable that was most strongly
associated with the outcome based on prior evidence. Three Phase I risk predictors, X1, X2, and
X3, were generated from the standard normal distribution, uniform distribution between 0 and 1,
and binomial distribution with success probability 0.2, respectively. Phase II variables consisted of
one single predictor Z that followed the standard normal distribution. The binary outcome Y was
generated from the logistic regression model (2.1), with X = (X1, X2, X3). We set the log OR
parameters for (X, Z) as {log(0.6), log(1.6), log(0.6), log(1.5)}, so that X1 and X3 were negatively
associated with Y and X2 was positively associated. We chose α = log(0.03) so that the preva-
lence of Y , p(Y = 1), was around 4%. We generated a cohort of size N = 3000 (Phase I) and
selected all cases and stratum-matched controls at a ratio of 1 : 2 into Phase II using the three
sampling strategies. Under the case-control design, we randomly selected all cases and twice as
many controls from phase I. Under the balanced design, we created four sampling strata based on
quartiles of X2 and then selected all cases and twice as many controls in each stratum. Under the
E-balanced design, similar stratified sampling was performed, but the stratum S was defined based
on a linear combination of X1, X2, and X3. We assumed that information on the predictiveness of
(X1, X2, X3) is available externally and summarized by the following logistic regression model:
pe(x1, x2, x3) =
exp(α′ + α1x1 + α2x2 + α3x3)
1 + exp(α′ + α1x1 + α2x2 + α3x3)
. (2.5)
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Phase I subjects are classified into four strata based on the estimated risk pe(x1, x2, x3) such that
each stratum contained roughly equal numbers of cases. We considered two sets of OR parameters
for this model. In one (“E-balanced I”), the values were chosen so that the risk distribution based
on external information was reasonably close to the true risk distribution based on model (2.1). In
the other (“E-balanced II”), we let the values deviate further from those in model (2.1), and also
reversed the association between (X1, X3) and Y . The risk distribution shifted by a reasonably
large amount compared to the truth. In both cases, the value of α′ was set so that the prevalence
of Y was comparable to that under model (2.1). The two corresponding risk distributions are dis-
played in Figure 2.1. Results from E-balanced II will inform the efficiency of our proposed design
0.0 0.1 0.2 0.3 0.4 0.5
0
5
1 0
1 5
2 0
2 5
3 0
Risk
P r
o b
a b
i l i t
y  
D e
n s
i t y
Truth
E−balanced I
E−balanced II
Figure 2.1: Risk distributions under three different prior risk models in the simulation study. “Truth”
denotes the true model (1) with (β1, β2, β3)=(log(0.6), log(1.6), log(0.6)). “E-balanced I” denotes
the same model but with log OR parameters equal to (β1, β2, β3)=(log(0.5), log(1.7), log(0.7)). “E-
balanced II” denotes the same model with log OR parameters equal to (β1, β2, β3) = (log(1.1),
log(2.2), log(1.1)).
when external information on the association between the outcome and Phase I variables agrees
poorly with that in the data. All three proposed methods, ML, PL, and WL, were then applied to
analyze each of 1000 simulated datasets. We also obtained estimates using full cohort data as the
benchmark. For PCF and PNF, we considered threshold values q = 0.2 for PCF and p = 0.9 for
PNF.
The results are summarized in Table 2.1. The averaged estimates of the three accuracy measures
by all the three methods were close to the benchmark values. The averaged asymptotic standard
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error (“ASE”) estimates were all close to the empirical standard errors. The ML estimates always
had the smallest asymptotic standard error estimates regardless of the sampling strategies, while
the WL estimates had the largest as expected. The PL estimates mostly had similar standard er-
rors as the ML estimates under E-balanced I when information used for stratification was relatively
precise, although they became less efficient under the other two sampling designs. For example,
under E-balanced I, estimates for PCF0.2 by ML, PL, and WL were 0.433 (ASE: 0.038; 95% CI:
0.359, 0.507), 0.434 (ASE: 0.038; 95% CI: 0.360, 0.508), and 0.435 (ASE: 0.040; 95% CI: 0.357,
0.513), and the relative efficiency improvement of ML over WL was 10.8%. For PNF0.9, the im-
provement was 17.9%. Under the balanced and case-control sampling, the efficiency improvement
became greater: 25% and 36% for PCF0.2 and 28% and 33% for PNF0.9, respectively. These larger
improvements most likely resulted from the higher efficiency for estimating the predictor distribution
in the ML method, since the efficiency gain of ML compared to WL for estimating the ORs were only
around 8% and 10%, respectively (data not shown). Across all designs, the efficiency of estimating
AUC was similar for all three methods, although WL was slightly less efficient.
The efficiency of the E-balanced design appeared to depend on how precise the external infor-
mation was for the relationship between Phase I predictors (X1, X2, X3) and outcome Y . Un-
der E-balanced I where the sampling model (2.5) was close to the true relationship induced by
model (2.1), it yielded the most efficient estimates for each estimation method. The balanced and
case-control designs had similar efficiencies although the former was at times slightly better. For
estimating PCF0.2, the efficiency of the E-balanced I design relative to the balanced and case-
control design was around 22.0% by ML, 34.0% by PL, and 27.0% by WL. Compared to WL under
the least efficient case-control design, which is the commonly used approach under the most widely
used sampling design, ML under the E-balanced I gained around 40% efficiency for estimating PCF
and PNF and 25% for AUC. The efficiency advantage over the other two sampling strategies largely
vanished when the external information deviated substantially from the truth under E-balanced II,
although there was some improvement (less than 10%) for WL.
2.4. The Analysis of a Study of Gestational Diabetes Mellitus
Using data from the GDM study described in Introduction, we applied our proposed methods to
develop a preliminary model for the risk of GDM. We considered conventional risk factors and
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Table 2.1: Estimates of the three predictive accuracy measures and their asymptotic standard errors
under four Phase II sampling designs. Results are presented as the mean estimate (the empirical
standard error estimate, the mean asymptotic standard error estimate).
ML PL WL
E-Balanced Design I
P̂CF0.2 0.433 (0.038, 0.038) 0.434 (0.038, 0.038) 0.435 (0.040, 0.041)
P̂NF0.9 0.722 (0.036, 0.035) 0.723 (0.036, 0.036) 0.723 (0.038, 0.038)
ÂUC 0.689 (0.025, 0.025) 0.689 (0.026, 0.025) 0.689 (0.027, 0.027)
Balanced Design
P̂CF0.2 0.435 (0.042, 0.042) 0.436 (0.044, 0.043) 0.437 (0.045, 0.047)
P̂NF0.9 0.720 (0.038, 0.038) 0.721 (0.039, 0.039) 0.719 (0.040, 0.043)
ÂUC 0.690 (0.029, 0.028) 0.690 (0.029, 0.029) 0.691 (0.030, 0.029)
Case-control Design
P̂CF0.2 0.439 (0.043, 0.042) 0.441 (0.043, 0.043) 0.443 (0.047, 0.049)
P̂NF0.9 0.715 (0.039, 0.039) 0.716 (0.039, 0.039) 0.713 (0.043, 0.045)
ÂUC 0.689 (0.028, 0.028) 0.689 (0.028, 0.028) 0.690 (0.029, 0.029)
E-Balanced Design II
P̂CF0.2 0.436 (0.042, 0.042) 0.436 (0.045, 0.044) 0.437 (0.045, 0.047)
P̂NF0.9 0.719 (0.038, 0.038) 0.720 (0.040, 0.040) 0.718 (0.041, 0.043)
ÂUC 0.688 (0.029, 0.029) 0.688 (0.029, 0.030) 0.689 (0.030, 0.031)
Benchmark Using the Full Cohort
P̂CF0.2 0.432 (0.034, 0.034)
P̂NF0.9 0.720 (0.031, 0.031)
ÂUC 0.686 (0.023, 0.023)
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glucose level, where the latter was measured only on the case-control subset. Complete data for
both conventional risk predictors and glucose level was available for 104 cases and 208 controls,
who were included in our analysis. We additionally assessed the efficiency of the E-balanced
design by generating two-phase data involving only conventional risk factors, using each of the
three sampling approaches as described in the simulation study. We discarded data on BMI for
subjects not selected into Phase II, thereby treating BMI as the Phase II variable.
We used a logistic regression model to describe the relationship between gestational diabetes and
all risk predictors. The two matching variables, age and race, are predictive of the risk of gestational
diabetes (Berkowitz et al., 1992). We ignored gestational age in all analyses because it turned out
not to be significantly associated with the risk of GDM in the full cohort. Because cases and
controls in this study were more finely matched compared to the frequency-matching, conditional
logistic regression analysis should have been the most appropriate approach to fitting the logistic
regression model to estimate the OR parameters. But the effects of the matching variables, age and
race, could not be estimated in such an analysis. We conducted an unconditional logistic regression
analysis with matching variables adjusted for, and found that the estimates were very close to those
from the conditional analysis (Table 2.2). Consequently, we adopted the unconditional regression
analysis, treating the whole cohort as Phase I sample and the nested case-control subset as Phase
II sample. We post-stratified the whole cohort by age (above or below 50 years) and race in all the
three methods in the model development. The resultant data structure aligns with the two-phase
design, allowing us to apply the proposed methods for analysis (Breslow and Chatterjee, 1999;
Lawless, Kalbfleisch, and Wild, 1999). For WL, the sampling probabilities for cases were all equal to
one, but for controls, they were calculated as the number of Phase II controls divided by the number
of Phase I controls within each post-stratum. For the purpose of comparison, we also developed a
model that included only conventional risk predictors using data from the full cohort and estimated
the corresponding predictive accuracy measures. Age and BMI were fitted as continuous variables
after exploring their functional forms by local polynomial regression, and race and family history
were fitted as categorical variables. We dichotomized glucose level at median 94 in this analysis.
The estimates of the OR parameters are provided in Table 2.2, and those for the three predictive
accuracy measures are provided in Table 2.3. Higher BMI, positive family history of diabetes, and
higher glucose level appeared to be positively associated with the risk of gestational diabetes.
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The OR for the glucose level was estimated to be 2.95 (95% CI: 1.62, 5.39) by ML. To facilitate
comparison with results when only conventional risk factors are included, the predictive accuracy
measures were calculated with age and race included in the model, even if they were not significant.
Results were largely similar to those when age and race were excluded (data not shown). If 20% of
the women in the population at the highest risk by this model are screened for gestational diabetes,
51.5% (95% CI: 42.6%, 60.4%) of the cases can be identified when ML and PL are used. The
corresponding estimates based on WL were 52.6% (95% CI: 42.1%, 63.1%). To be able to identify
90% of the cases, 69.8% (95% CI: 61.1%, 78.5%) of the population at the highest risk need to be
followed according to the ML method. The AUC was estimated to be 0.673 (95% CI: 0.614, 0.732)
by ML. Estimates by the other two methods were very close, and PL had similar while WL had
larger estimated standard errors. Glucose level appeared to have predictive values independent of
conventional risk predictors. With the glucose level included in the model, PCF0.2, PNF0.9, and AUC
were estimated to increase by 2.9%, 1.4%, and 1.6%, respectively. We note that a more predictive
model should have lower PNF values, but here the positive difference 1.4% was not expected to be
significant.
Table 2.3: Estimated predictive accuracy measures and standard errors for the prediction models
in Table 2.2, one using conventional predictors only (“Conventional predictors”), and the other using
both conventional predictors and glucose level fitted using each of the three methods (“ML”, “PL”,
“WL”).
Conventional predictors Conventional predictors & Glucose levelML PL WL
P̂CF0.2 0.486 (0.037) 0.515 (0.045) 0.515 (0.045) 0.526 (0.053)
P̂NF0.9 0.684 (0.036) 0.698 (0.044) 0.692 (0.045) 0.718 (0.047)
ÂUC 0.657 (0.024) 0.673 (0.030) 0.674 (0.030) 0.677 (0.037)
To compare the efficiency of the three estimation methods and Phase II sampling strategies, we
considered the conventional risk predictors only under the same model as that in Table 2.3 (the
second column). We applied each of the three sampling methods, the E-balanced, case-control,
and balanced sampling, for selecting Phase II subjects, with age, race, and family history consid-
ered as Phase I variables (X) and BMI as Phase II variable (Z). Data for BMI was retained only for
Phase II subjects and deleted in the rest in the analysis. Under the E-balanced sampling, we used
the OR parameters (1.63, 2.61, 1.43) for every 5-year increase in age, Asian race, and family history
of diabetes reported by Berkowitz et al. (1992). These ORs turned out to be reasonably close to
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the ones in our analysis (Table 2.2). Phase I subjects were then classified into three strata based
on the predicted risk calculated with these ORs. Under the balanced sampling, the Phase I strata
were simply defined as three age groups (< 30, 30∼35, > 35). From each stratum, 20 cases and
20 controls were selected into Phase II. Under the case-control sampling, 60 cases and 60 controls
were randomly selected from those who developed or did not develop GDM. We generated 500
two-phase samples with each sampling strategy, and the results that summarized the 500 corre-
sponding sets of estimates are presented in Table 2.4. ML appeared to be the most efficient and
WL the least efficient, which is best shown by comparing the ratio between the averaged estimate
and the standard error. The E-balanced sampling always led to smaller standard errors compared
with the balanced sampling, but the improvement was marginal in the current analysis. We con-
jecture that the improvement would be greater if the number of cases were larger to allow for finer
stratification of the Phase I data. The averaged estimates appeared to be slightly biased upwards
compared with the full cohort analysis (“Benchmark estimates”). Our exploration showed that was
due to the small number of cases and controls.
Table 2.4: Estimated predictive accuracy measures and standard errors of conventional risk predic-
tors for predicting the risk of gestational diabetes mellitus under different sampling designs. Results
are presented as the mean estimate (the mean asymptotic standard error estimate)
.
ML PL WL
E-Balanced Design
P̂CF0.2 0.531 (0.096) 0.550 (0.104) 0.551 (0.119)
P̂NF0.9 0.669 (0.082) 0.660 (0.103) 0.650 (0.118)
ÂUC 0.684 (0.063) 0.693 (0.078) 0.692 (0.096)
Balanced Design
P̂CF0.2 0.544 (0.098) 0.558 (0.120) 0.551 (0.123)
P̂NF0.9 0.657 (0.085) 0.654 (0.109) 0.652 (0.122)
ÂUC 0.691 (0.064) 0.698 (0.084) 0.692 (0.104)
Benchmark
P̂CF0.2 0.495 (0.038)
P̂NF0.9 0.679 (0.035)
ÂUC 0.665 (0.024)
2.5. Conclusion
Two-phase study design is a cost-effective option to collect expensive predictors for the develop-
ment of risk models. To predict the risk of a binary outcome, we developed an arsenal of statistical
approaches to estimate risk distribution and several popular statistical measures for quantifying
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predictive accuracy of the model. These methods differ in both statistical efficiency and ease of
implementation. The ML estimator had the highest efficiency in the simulation study and real data
analysis, and the PL estimator was a close competitor. Computation of the latter did not require
iteration and therefore was faster and stable. One may balance the computation burden and desire
for efficiency when deciding which method to use. The weighted likelihood estimator was the least
efficient, but its efficiency can be improved through augmentation (Robins, Rotnitzky, and Zhao,
1994). More interestingly, it is expected to converge to the same limit as that when the data is avail-
able for the full cohort, even when the prediction model deviates from the true relationship between
the outcome and predictors (Scott and Wild, 2002), an appealing robustness property that ML and
PL do not have. A comparison of the three methods under model misspecification will be pursued
in future work.
In order to analyze the GDM study example, we treated Phase II data as if it were collected using a
stratified case-control design instead of the matched case-control design that was actually adopted.
We justified our analysis by very similar estimates from the conditional and unconditional logistic
regression analyses for BMI and family history which were measured on the full cohort. In general,
we do not claim that our methods are universally applicable for analyzing matched case-control
data supplemented with cohort information. To our best knowledge, two-phase methods are yet to
be developed to rigorously accommodate individual matching, although such methods are available
for studying time-to-event outcomes (Samuelsen, 1997). In particular, the WL method cannot be
applied because subjects who are not eligible to match as controls for any case (e.g., in the GDM
example, those who did not fall into the 2-year range of any case’s age) have sampling probability
equal to zero. The PL and ML methods would not apply either because they required stratified
sampling as reflected in their respective likelihood functions. On the other hand, performing un-
conditional logistic regression is not uncommon for analyzing matched case-control data when the
matching is not very fine.
We proposed selecting Phase II subjects based on existing information on the estimated risk with
only Phase I variables for improved estimation efficiency. This strategy is an extension of the bal-
anced design where Phase II subjects are selected based on combined values of individual Phase I
predictors. Post-stratification based on prior predicted risks to increase statistical efficiency in fitting
a risk model enriched with new predictors has been considered in the literature (Cai and Zheng,
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2012). But the efficiency of sampling Phase II subjects utilizing prior risk estimates compared to
the case-control and balanced sampling schemes has not been explored. Through over-sampling
of subjects with more extreme risks, this design was shown to lead to improved efficiency for esti-
mating risk distribution and predictive accuracy measures in our numerical studies. The efficiency
gain increases when the prior risk estimates are closer to the risks estimated from Phase I data.
Although it is difficult to perform theoretical studies on the efficiency of this design, the fact that it is
an extension of the balanced design along with our numerical results supports its practical useful-
ness. Instead of relying on external data to assess prior risk, one may fit a working model to Phase
I variables and perform Phase II sampling accordingly. While efficiency gain is expected, this incurs
serious methodological challenges partly because the sampling across individuals now becomes
dependent. We will study this sampling strategy in the context of risk prediction in future work.
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CHAPTER 3
A SEMIPARAMETRIC APPROACH TO DEVELOPING WELL-CALIBRATED MODELS
FOR PREDICTING THE RISK OF BINARY OUTCOMES USING CASE-CONTROL DATA
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3.1. Introduction
Accurate risk prediction is central to precision medicine and precision disease prevention. Modern
technology has enabled widespead efforts of biomarker discovery, promising great possibilities of
improving risk prediction for human diseases. For putative biomarkers, it is of ultmost interest to
evaluate their added values for prediction. But this is a challenging task. The model development
requires data for disease status, biomarkers, as well as established risk predictors from a sample
that is of sufficiently large size to allow stable model fitting. In practice, initial investigation efforts
most often afford collection of data only from a small number of subjects, who are often recruited
using a case-control study design. Cases or controls are not necessarily representative of the dis-
eased or non-diseased in the target population for prediction. For example, the breast cancer risk
assessment tool (BCRAT) was developed using data from a case-control study of breast cancer that
was nested in the Breast Cancer Detection and Demonstration Project (BCDDP). The participants
were recruited from women who volunteered to undergo mammographic screening. The BCDDP
women turned out to have higher average risk of breast cancer than the general U.S. Caucasian
women. The distribution of BCRAT risk predictors in the BCDDP also differs from that estimated
from the National Health Interview Survey (NHIS), where the latter better represents the general
Caucasian woman population. In an ongoing study on evaluating the predictiveness of volumet-
ric breast density, cases and controls were recruited from the University of Pennsylvania health
system. The odds ratio estimates for the BCRAT risk predictors were quite different from those
used in the BCRAT. The study sample used for model development may also have been assem-
bled cross-sectionally, which often can not be treated as a random sample selected from the target
population.
Once a model is developed, the subsequent validation, which is necessary for establishing practical
usefulness of the model, requires data that is collected from sources independent of those for
model development. In particular, good calibration is essential in order to inform patients about
their risks and make risk-based decision. The BCRAT was calibrated to the composite breast
cancer rates reported in the Surveillance, Epidemiology, End Results program, making it a useful
tool for projecting individualized risk for the U.S. Caucasian women. While data for the outcome and
standard risk predictors may well be available from existing studies or can be easily obtained, it is
usually much more challenging to obtain biomarker data. For example, it is not possible to genotype
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BCDDP cases and controls because blood samples were not collected. The resources required
to validate the predictiveness of metabolomic biomarkers are non-trivial partly due to the cost of
metabolomics technology. Lack of independent validation data has been an obvious factor that
hinders translation of biomarkers to clinics. Percent mammographic density was incorporated as a
strong risk predictor into the BCRAT (Chen et al., 2006), and led to an increase in the area under the
ROC curve that is comparable to that by incorporation of breast cancer risk SNPs identified to date.
However, validation studies has yet to be conducted after more than 10 years since this updated
model was published. Even if the data for validation is fully available, the sample size may limit the
power for detecting lack of calibration. Recent work shows that greater than 10,000 subjects were
required in order to detect meaningful differences between the predicted and observed risks in the
upper tail of the risk distribution (Chatterjee et al., 2016).
Fortunately, data from multiple sources becomes more and more available that can be exploited
to enhance model development and validation, which may compensate the scarce of biomarker
data. The incidence rates for common diseases in the U.S. are publically available. Population
level data for standard risk predictors is frequently available from national and international efforts
or existing cohort studies. For example, the BCRAT risk predictors are fully represented in the
National Health Interview Survey (NHIS III). The relationship between the outcome and standard
risk predictors may have been assessed in multiple studies, or a risk prediction model that uses only
standard predictors may have been developed and validated extensively. Data may be available
for characterizing the relationship between biomarkers and standard risk predictors. Aiming to
exploit these existing resources for model development and validation, we develop novel statistical
methods for predicting the risk of a binary outcome using the logistic regression model.
Considering a scenario where a well calibrated model based on standard predictors exists, we focus
on a central task of incorporating new risk predictors into the existing model, which henceforth is
referred to as the “base model”. We assume that data on the outcome and all predictors is available
from a case-control sample. The standard method for analysis would be to fit a prospective logistic
regression model that includes an offset term to adjust for case-control sampling. Here, we develop
a novel constrained maximum likelihood method, which has four features that distinguish it from
the standard method. First, our method ensures that the new model calibrates similarly as the
base model, in the sense that the predicted risk by the new model in the population strata defined
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by standard predictors is comparable to that by the base model. Because the base model is well
calibrated, such agreement between the two models lends support to the good calibration of the
new model in the absence of independent validation data. A similar idea of indirect calibration
was successfully applied for updating the BCRAT by incorporating percent mammographic density
(Chen et al., 2006). Second, our method explicitly recognizes that the underlying population from
which the case-control sample was assembled may not have the same distribution of standard risk
predictors as the target population for prediction. Third, our method accommodates the known
distribution of standard risk predictors in the target population, while relying on the case-control
data for information on biomarkers. Fouth, our method more readily accommodates smaller sample
sizes because of its high statistical efficiency.
Our method is based on maximizing the likelihood function under the constraints translated from
the base model and external information on standard risk predictors. Using a parametric regres-
sion model to describe the relationship between the biomarker and standard risk predictors, we
apply the Lagrange multiplier approach to deriving the profile likelihood for the Euclidean parame-
ters. Constrained maximum likelihood methods have recently been developed to increase statis-
tical efficiency for estimating odds ratio association parameters by exploiting external information
through constraints (Chatterjee et al., 2016; Qin et al., 2015). Putting into the current context,
Qin et al. (2015) exploited known outcome prevalence in strata defined by standard predictors to
increase statistical efficiency, where the underlying population for the case-control sample shares
the same risk and predictor distributions that define the stratum-specific prevalences. Chatterjee
et al. (2016) exploited a known regression relationship between the outcome and standard pre-
dictors to increase statistical efficiency, when the joint distribution for both standard predictors and
biomarkers is known externally. Our method differs in important ways: it exploits stratum-specific
prevalence similarly as Qin et al. (2015), but accommodates known distribution of standard predic-
tors for the target population of prediction while requiring information on biomarkers only from the
case-control data. These differences lead to important practical implications: the model developed
using our method calibrates to the target population, where the calibration is defined by the agree-
ment between the predicted and estimated risks in discrete population strata as commonly done
for assessing goodness-of-fit of regression models. These differences also call for new theoretical
development for statistical inference.
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The rest of this Chapter is organized as follows. We describe our proposed method and inference
procedures in Section 3.2. In Section 3.3, we assess the finite sample performance of our method
using simulated data, considering small, moderate, or large differences between the source pop-
ulation of the case-control sample and the target population and statistical efficiency. In Section
3.4, we will apply our method to analyze the BCDDP data to develop a logistic regression model
for predicting the 5-year risk of breast cancer, using both the BCRAT risk predictors and percent
mammographic density. We estimate the distribution of the BCRAT risk predictors from the Na-
tional Health Interview Survey (NIHS III), and use a Beta-regression model for the distribution of
percent mammographic density given the BCRAT risk predictors. Therefore, implicitly, we assume
the latter to be the same in the BCDDP and general U.S. Caucasian woman population. We re-
port estimates for both odds ratio parameters and parameters in the Beta-regression model by the
proposed constrained maximum likelihood method.
3.2. The Method
3.2.1. Notation and likelihood function
Let Y denote the binary outcome status with Y = 1 indicating cases and Y = 0 indicating con-
trols. Let X and Z denote the standard risk predictors and biomarkers, respectively. We con-
sider that data for (X,Z) is collected from a frequency-matched case-control sample, where cases
and controls are matched on a random variable S with M levels. We consider that S is an es-
tablished predictor, such as age categories and ethnicity. Let n1s and n0s denote the respective
number of cases and controls in stratum s, s = 1, 2, . . . ,M . Suppose that X and Z have K and
L unique values observed in the data, {xk, k = 1, ...,K} and {zl, l = 1, ..., L}, respectively. Let
n1skl and n0skl represent the number of cases and controls in stratum s with X = xk and Z = zl,∑
k
∑
l niskl = nis, i = 0, 1, s = 1, ...,M . Our goal is to fit a logistic regression model for predicting
Y with (S,X,Z):
P (Y = 1|S = s,X = xk,Z = zl) = exp{αs + β
T
x xk + β
T
z zl}
1 + exp{αs + βTx xk + βTz zl}
, (3.1)
where αs, s = 1, ...,M is the stratum-specific intercept, (βx,βz) are the log odds ratio parameters for
(X,Z). Let pisk = P (X = xk|S = s), k = 1, ...,K, s = 1, ...,M denote the empirical distribution of X
in stratum S = s, and we use a parametric model fτ (z|s,xk) to describe the conditional distribution
33
of Z given (X, S), where τ is a vector of Euclidean parameters. Let Piskl ≡ P (Y = i|S = s,X =
xk,Z = zl). The empirical log-likelihood function of the case-control data can be derived as
l(α,β, τ ,pi) = log
1∏
i=0
M∏
s=1
K∏
k=1
L∏
l=1
P (X = xk,Z = zl|Y = i, S = s)niskl
= log
1∏
i=0
M∏
s=1
K∏
k=1
L∏
l=1
{
Pisklpiskfτ (zl|s,xk)
P (Y = i|S = s)
}niskl
=
1∑
i=0
M∑
s=1
K∑
k=1
L∑
l=1
niakl logPiakl +
M∑
s=1
K∑
k=1
n+sk+ log pisk
+
M∑
s=1
K∑
k=1
L∑
l=1
n+skl log fτ (zl|s,xk)−
1∑
i=0
M∑
s=1
nis++ log
{
K∑
k=1
L∑
l=1
Pisklpiskfτ (zl|s,xk)
}
,
where α = {αs : s = 1, ...,M},pi = {pisk : s = 1, ...,M ; k = 1, ...,K},β = (βx,βz). Since pisk is the
empirical probability mass function, it should satisfy the following constraints:
K∑
k=1
pisk = 1, s = 1, ...,M. (3.2)
We assume that a risk prediction model based on risk predictors (S,X) is available and well-
calibrated for strata defined by (S,X), and denote the predicted risk as ϕ(S,X). The stratum-
specific distribution for X in the target population of prediction, P e(X = xk|S = s), denoted by
δsk, is known from external sources, where superscript “e” here and after indicates “external”. We
explicitly allow δsk and pisk to be different, that is, δsk 6= pisk. Within each stratum s, we categorize
predicted risk ϕ into Is intervals, and use asr and bsr to denote the beginning and end of each
interval. We assume that the calibration of the model ϕ(S,X) was assessed in external studies by
comparing the averaged predicted risk within each risk interval, defined as
P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr), s = 1, ...,M, r = 1, ..., Is,
with the “observed” average risk. We impose the equality of these averaged risks between the new
model (3.1) and model ϕ(S,X), thereby ensuring a good calibration performance of the new model
in stratum defined by (S,X). The resultant constraints are expressed as below:
P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr) =
∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
, (3.3)
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where s = 1, ...,M, r = 1, ..., Is.
3.2.2. Constrained maximum likelihood for estimating (α,β, τ )
We propose to estimate (α,β, τ ) by maximizing the log-likelihood function l(α,β, τ ,pi) subject to
constraints (3.2) and (3.3). Because the number of nuisance parameter pisk can potentially be large,
we derive the profile likelihood for parameters (α,β, τ ) using the method of Lagrange multipliers.
The objective function is written as
g∗(α,β, τ ,pi,λ,λ∗) = l(α,β, τ ,pi) +
M∑
s=1
λ∗s
{
K∑
k=1
pisk − 1
}
+
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}
.
Let λ and λ∗ denote the two sets of Lagrange multipliers (λsr : s = 1, ...,M, r = 1, ..., Is) and
(λ∗s : s = 1, ...,M), respectively. By maximizing function g∗(α,β, τ ,pi,λ,λ
∗) over pi with parameters
(α,β, τ ) fixed, we can show that λ∗ = 0 and are able to express pi as a function of (α,β, τ ,µ),
pˆisk(αs,β, τ , µis) =
n+sk+
n+s++
∑1
i=0 µis
∑L
l=1 Pisklfτ (zl|s,xk)
,
µis =
nis++
n+s++
∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
,
where µ = (µis : i = 0, 1, s = 1, ...M) has a dimension that equals twice the number of strata
and therefore is much smaller than K. µ can be treated as a vector of independent parameters in
subsequet estimation. The detailed calculations are provided in the Appendices. Upon plugging p̂i
back into g∗(α,β, τ ,pi,λ,λ∗), we obtain the constrained profile likelihood function for (α,β, τ ) as
g(α,β, τ ,µ,λ) =
1∑
i=0
M∑
s=1
K∑
k=1
L∑
l=1
niskl log
{
Pisklfτ (zl|s,xk)µis∑1
i=0 µis
∑L
l=1 Pisklfτ (zl|s,xk)
}
+
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}
.
(3.4)
In the above development, we note that the second constraint did not contribute to the deriva-
tion because of the absence of pisk due to δsk 6= pisk. This, together with the needed parametric
relationship between Z and (S,X), defines the novelty of our profile likelihood function.
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We maximize profile likelihood function (3.4) jointly with respect to all the unknown parameters
(α,β, τ ,µ,λ) to obtain estimates of (α,β, τ ). We derive the score functions by taking the first
derivative of the function (3.4) with respect to each component of the unknown parameters, (Sα,
Sβ, Sτ , Sµ, Sλ). The detailed derivations are provided in the Appendices. The maximum likelihood
estimates (α̂, β̂, τ̂ , µ̂, λ̂) are obtained via solving
{
STα, S
T
β , S
T
τ , S
T
µ , S
T
λ
}T
= 0. The identifiability,
consistency, and asymptotic normality of the estimators are given in the Theorems below.
3.2.3. Identifiability and consistency
When the model in (3.1) is correctly specified, the identifiability of the parameters α,β, τ ,pi has
been shown in the literature. Let θ = (αT ,βT , τT ,piT )T . For simplicity, we assume the parameter
space Θ is bounded. We show that the constrained MLE θ̂ converges to the unique true parameter
θ0 in probability. The details of the proof are provided in the Appendices. We also consider a more
realistic and common case in the setting of risk prediction, where the model in (3.1) is arbitrary and
not necessarily the true model. In this case, we need to establish the identifiability first, i.e., there
are no two sets of parameters α,β, τ ,pi and α˜, β˜, τ˜ , p˜i so that they both satisfy the constraints in
(3.2) and (3.3), and P (x, z|y, s,α,β, τ ,pi) = P (x, z|y, s, α˜, β˜, τ˜ , p˜i) for all (x, z, y, s) combinations.
The detailed proof has been provided in the Appendices. Later, we show the consistency of the
constrained maximum likelihood estimator and details are given in the Appendices again.
3.2.4. Asymptotic properties
Regardless of the model in (3.1) is correct or misspecified, we have shown that the constrained
MLE θ̂n converges to θ0 defined according to the specific situation. The constraint in (3.2) enables
us to write pisK = 1 −
∑K−1
k=1 pisk hence eliminate the parameter pisK . Likewise, because P1skl is a
monotonically increasing funcion of αs, the constraint in (3.3) enables us to solve for αs uniquely
as a function of other parameters, hence eliminate the parameter αs, for s = 1, . . . ,M when Is =
1. When Is > 1, we will be able to eliminate other parameters as well. Denote the remaining
parameters ψ and write the parameters that are determined by the constraints γ(ψ). Note that
the functional relation γ(ψ) does not depend on data. With a slight abuse of notation, we use
l{ψ,γ(ψ)} to denote the loglikelihood function of ψ. The constrained maximization then can be
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equivalently written as maximizing
Mn(ψ) ≡ n−1l{ψ,γ(ψ)}
with respect to ψ and we have shown that {ψ̂n,γ(ψ̂n)} → θ0 in probability. This means we have
= n1/2
∂Mn(ψ)
∂ψ
∣∣
ψ=ψ̂n
= n1/2
∂Mn(ψ)
∂ψ
∣∣
ψ=ψ0
+
∂2Mn(ψ)
∂ψ∂ψT
∣∣
ψ=ψ∗n
1/2(ψ̂n −ψ0),
where ψ∗ is on the line connecting ψ0 and ψ̂n. Thus, we obtain the expansion
n1/2(ψ̂n −ψ0) = −
[
E
{
∂2Mn(ψ0)
∂ψ∂ψT0
}]−1
n1/2
∂Mn(ψ0)
∂ψ0
+ op(1).
This leads to that
√
n(ψ̂n −ψ0)→ N(0,V ψ) in distribution, where
V ψ =
[
E
{
∂2Mn(ψ0)
∂ψ∂ψT0
}]−1
var
{
n1/2
∂Mn(ψ0)
∂ψ0
}[
E
{
∂2Mn(ψ0)
∂ψ∂ψT0
}T]−1
.
Because θ̂ = {ψ̂T ,γ(ψ̂)T }T , we further have that √n(θ̂n − θ0) → N(0,V θ) in distribution, where
V θ = AV ψA
T and
A =
 I∂γ(ψ0)
∂ψT0
 .
3.3. The BCRAT and Percent Mammographic Density: Analysis of Data from the
Breast Cancer Detection and Demonstration Project (BCDDP)
We applied our proposed method to analyze data from the BCDDP to develop a logistic regression
model for predicting the risk of breast cancer for Caucasian women in the next five years follow-
ing predictor meausurement. We intended to include both the BCRAT risk predictors and percent
mammographic density (PD) as predictors. The BCRAT predictors include age at menarche (Age-
men), age at first live birth (Ageflb), number of previous breast biopsies (Nbiops), and number of
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first-degree relatives (mother/sisters; Numrel) who had breast cancer. PD, the percent of dense
area on the mammogram image as a measure of breast density, has been established as one of
the strongest risk predictors for breast cancer (Boyd et al., 1995; Byrne et al., 1995). The odds ratio
function used in the BCRAT was developed from an age-stratified case-control study nested within
the BCDDP, which included 2,808 cases and 3,119 controls. A subset of 1,217 cases and 1,616
controls had PD measurements. The details of this study were reported previously (Chen et al.,
2006; 2008), where it was shown that the availability of PD only depended on the case-control sta-
tus and age strata. Here, we analyzed data for the 2,833 (1217+1616) subjects who had complete
predictors data, as inclusion of subjects who did not have PD data requires non-trivial extension of
our method. Because weight confounded the relationship between breast cancer risk and PD, we
also included weight as a predictor as in the previous work (Chen et al., 2006, 2008) The codings
of BCRAT predictors and weight were the same as those in Chen et al. (2006), and they were all
fitted as ordinal variables. In the model, we considered two age strata defined as S = 1 if age ≤
50 and S = 2 otherwise, and finer categorization can be adopted in the same manner. We fitted
model (3.1) with X=(Ageflb, Agemen, Nbiops, Numrel, Weight) and Z=PD. In the data, around 10%
of the subjects had zero values for PD, which we conjectured reflected both truly no dense tissues
and PD values that were below the detection limit. We used a zero-inflated Beta regression model
for the distribution of Z to accommodate the excess zero value (Chen and Chen, 2015). Let Zmin
denote the minimal value that PD was detectable. The probability density function of Z can then be
written as follows:
P (Z|S,X;γ,ω, ρ) = p(Z = 0)I{Z=0}p(Z > 0)I{Z>0}
= [ρ+ (1− ρ)Beta(Z < Zmin|X, S;γ,ω)]I{Z=0}
× [(1− ρ)Beta(Z|X, S;γ,ω)]I{Z>0} ,
where ρ denoted the probability that Z truly took zero value and 1 − ρ the probability that Z was
generated from a Beta regression model. The model was defined by its mean parameter κ and the
precision parameter φ such that Beta(Z|S,X;γ,ω) = Beta(Z|κ, φ), where logit(κ) = (1, S,X)γ,
log(φ) = (1, S,X)ω. In the logistic regression model (3.1), we categorized Z into 10 groups for tak-
ing values 0, 1-9 for Z = 0 or Z ∈ (0, Zmin), [Zmin, 0.1), [0.1, 0.2), ..., [0.8, 1), respectively, denoted
by Zc.
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To ensure a good calibration performance of our model, i.e., to accurately predict the expected num-
ber of breast cancer cases in defined population subgroups, we imposed the constraints based on
5-year absolute risks predicted from the BCRAT. Since the BCRAT has been shown to be generally
well-calibrated in previous validation studies (Bondy et al., 1994; Costantino et al., 1999; Rockhill
et al., 2001), by equating the prediction performance of our new model to that of the BCRAT, we
would successfully maintain this “well-calibration” property. Let ϕB(T1, T2,XB) denote the BCRAT
absolute risk estimate starting from age T1 till T2 given XB=(Ageflb, Agemen, Nbiops, Numrel),
which can be calculated online (http://www.cancer.gov/bcrisktool). The superscript “B” indicates
“BCRAT”. We calculated ϕB(S,XB) as the weighted average of ϕB(T1, T2,XB) with T1, T2 ∈ S,
T2 − T1 = 5, and weight equal to Pr(age ∈ [T1, T2]) as estimated from NHIS. Further, we chose
quartiles of ϕB(S,XB) as the a′s and b′s in the constraints (3.3) and calculated P e(Y = 1|asr ≤
ϕB(S,XB) ≤ bsr), s = 1, 2, r = 1, 2, 3, 4. That is, we had a total of 8 constraints, 4 for each age stra-
tum. Together with the distribution P e(X|S) (Appendices) estimated from NHIS, whose variance
was ignored in the current analysis, we calculated P e(XB |S) = ∑Weight P e(XB ,Weight|S) and
obtained the averaged 5-year risk:
P e(Y = 1|ϕB(S = 1,XB) ∈ [a1, b1]) = (0.6%, 1.3%, 2.3%, 3.4%),
P e(Y = 1|ϕB(S = 2,XB) ∈ [a2, b2]) = (1.5%, 2.7%, 4.2%, 6.9%).
We used these eight numbers as the benchmark for risk prediction calibration. The resultant con-
straints were slightly different form compared to (3.3), because weight was originally not included
in XB and had to be averaged over in the constraint equations:
P e(Y = 1|asr ≤ ϕB(S,XB) ≤ bsr)
=
∑
XB :asr≤ϕB(S,XB)≤brs
∑
Weight
∑
Zc P (Y = 1|S,X, Zc)P e(X|S)P (Zc|S,X;γ,ω, ρ)∑
XB :asr≤ϕB(S,XB)≤bsr P
e(XB |S) .
For the comparison purpose, we also applied a “standard” method to analyze the same data. Es-
sentially the same method was applied to develop the BCRAT and other models for predicting the
risk of various cancer types (ref?). First, a prospective logistic regression model was fitted to ob-
tain the OR estimates for (X, Z). Then we fitted the Beta-regression model using data only from
the controls to obtain an approximate estimate of the PD distribution. Lastly, we plugged these
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estimates into the constraints above to solve for the stratum-specific intercept parameters corre-
sponding to the effect of S. The estimated standard errors for the OR estimates and (γ,ω, ρ) were
calculated using stantard MLE approach, while those for the intercept terms were estimated using
the delta method.
The results were summarized in Table 3.1. The estimated log ORs obtained by our method for risk
predictors could be quite different from those by the standard method. For Ageflb and Nbiops, the
estimates were 1.6 times larger. The direction of association between weight and breast cancer
was even reversed, changing from positive to negative. Because our method assumed the same
model relating the risk of breast cancer with predictors in the general Caucasian woman popula-
tion and the BCDDP population, these differences may indicate the effectiveness of our method for
pursuing good calibration. We conjecture that the differences in the predictor distribution, P (X|S),
between the BCDDP and NHIS largely drove the discrepancy in the two sets of OR estimates. As
shown in Figure 3.1, the distribution of weight in the BCDDP controls differed substantially from
that estimated from the NHIS in both age groups. On the other hand, the estimates for the log OR
of PDc and parameters involved in its distribution, except for the intercept term in the mean model
that turned out to be not significant, were similar between the two approaches. Our assumption of
the same distribution for PD in the general Caucasian woman population and BCDDP population,
might explain these consistencies. In the mean model for the PD distribution, Ageflb and Nbiops
were positively associated, and weight was negatively associated. Weight was the only significant
variable in the variance model, where larger weights appeared to be associated with lower variance
in PD. As indicated by the estimate of the mixture probability ρ which was significantly different from
zero, only around 10% subjects truely had no dense breast tissue as reflected on the mammogram
image, while the remaining 90% had non-zero but undetectable measurements. The estimates for
the log OR of PDc were similar by the two methods, and the estimated variance by our method was
10% smaller. The OR estimates for the age stratum, Agemen, and Numrel were also close, and
the estimated variance by our method was around 30% smaller for the latter two variables. Esti-
mates for parameters in the PD model were also similar, and our method yielded smaller standard
errors because both cases and controls were used compared with the standard method where only
controls were used.
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Table 3.1: Analysis of the BCDDP data: estimates of stratum-specific intercept terms and log ORs
for the BCRAT predictors, weight, and PD, together with estimates of parameters in the zero-inflated
Beta regression model for the distribution of PD. In the parenthesis are the corresponding estimates
of asymptotic standard errors. “cMLE” represents estimates from the proposed constrained maxi-
mum likelihood method, and “Standard” represents the estimates from the standard method.
Predictors cMLE Standard
Logistic Regression Model Intercept -6.105 (0.140) -6.751 (0.182)
for Breast Cancer Risk Age≥50 1.138 (0.030) 1.045 (0.035)
Ageflb 0.286 (0.033) 0.105 (0.049)
Agemen 0.241 (0.045) 0.213 (0.061)
Nbiops 0.460 (0.048) 0.174 (0.070)
Numrel 0.697 (0.019) 0.668 (0.090)
Weight -0.205 (0.033) 0.228 (0.044)
PDc 0.175 (0.017) 0.177 (0.018)
The PD distribution Intercept 0.165 (0.073) 0.035 (0.088)
Age≥50 -0.538 (0.048) -0.405 (0.057)
The mean model Ageflb 0.142 (0.027) 0.139 (0.033)
γ Nbiops 0.287 (0.035) 0.248 (0.045)
Weight -0.445 (0.025) -0.421 (0.033)
The variance model Intercept 1.396 (0.097) 1.478 (0.101)
ω Age≥50 0.198 (0.077) 0.202 (0.079)
Weight -0.093 (0.035) -0.121 (0.045)
Mixture probability ρ 0.096 (0.008) 0.105 (0.010)
3.4. Simulation Studies
We conducted extensive simulation studies to evaluate the finite sample performance of our pro-
posed methods. To make clear distinction between the target population of prediction and the
population from which the cases and controls were sampled, we set up the simulation scheme in
two steps. First, we defined a population where the true distribution of X, P e(X|S), was known, and
a well-calibrated risk prediction model based on (S,X) was available. Second, we generated data
for the established risk predictors (S,X) and biomarkers Z for a case-control sample, mimicking
the BCDDP case-control study described above.
3.4.1. Step 1: Define P e(X|S) and ϕ(S,X)
We considered that X consisted of four predictors, X = (X1, X2, X3, X4), where X1 ∼ N(0.25, 1)
was categorized into 4 groups by its quartiles, andX2 was generated from a Multinomial distribution
with probabilities (0.2, 0.6, 0.2). For X3 and X4, we generated two Poisson random variables with
mean 0.75 and 1.25, respectively, and assigned X3 values 0, 1, or 2 according to the first one
and X4 values 0, 1, ≥ 2 according to the second one. For the stratum variable S, we generated
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Figure 3.1: Distributions of weight for women with age ≤ 50 years or age > 50 years. The left
panel represents the distribution in the BCDDP controls. The right panel represents the distribution
estimated from the National Health Interview Survey (NHIS).
a Uniform random variable in the range of (30, 80), and assign S value 1 if this variable is less
than 50 and 2 otherwise. Therefore, X and S were mutually independent. The joint distribution
of predictors, P e(X|S), can then be expressed as ∏4i=1 P e(Xi), which was treated as known. We
assumed that the following logistic regression model for predicting the risk of Y based on (S,X),
where all variables in X were used as ordinal, was well calibrated:
ϕ(s,x;η) ≡ pe(Y = 1|s,x;η) = exp(η0 + η1I{s = 2}+ η2x1 + η3x2 + η4x3 + η5x4)
1 + exp(η0 + η1I{s = 2}+ η2x1 + η3x2 + η4x3 + η5x4) .
We set parameters (η0, η1, η2, η3, η4, η5) to be (−4.5, 1.0, 0.2, 0.15, 0.15, 0.65) so that the prevalence
of Y , P (Y = 1), was around 8.5%. Consistent with the common goodness-of-fit test of calibration,
we chose the quartiles of ϕ(s,x;η) as the cutoffs for each stratum used in the constraint (3.3).
Together with P e(X|S), we were able to obtain these cutoff values [asr, bsr], s = 1, 2, r = 1, 2, 3, 4
and the corresponding proportion of cases within each risk interval as
P e(Y = 1|ϕ(s = 1,x;η) ∈ [a1, b1]) = (1.9%, 3.1%, 5.0%, 8.1%),
P e(Y = 1|ϕ(s = 2,x;η) ∈ [a2, b2]) = (5.1%, 8.2%, 12.3%, 19.0%). (3.5)
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These eight numbers were considered as the calibration benchmark, leading to eight corresponding
constraints as described in (3.3).
3.4.2. Step 2: Generate the Case-Control Data
We considered three scenarios. In the first two scenarios, we generated X from distributions that
were different from those in Step 1 by using different parameter values. X1 was generated from
a standard normal distribution, X2 from a Multinomial distribution with probabilities (0.3, 0.4, 0.3),
and the Poisson distributions used for generating X3 and X4 had mean 1.25 and 1, respectively.
All four variables were coded the same way as in Step 1. In the third scenario, X followed the same
distribution as in Step 1. For all three scenarios, the stratum variable S was created the same way
as in Step 1, and we considered a single biomarker Z that followed the Beta regression model,
p(Z|s,x) ∼ Beta(κφ, φ− κφ), where
logit(κ) = γ0 + γ1I{s = 2}+ γ2x1 + γ3x3,
log(φ) = ω0 + ω1I{s = 2}+ ω2x2.
We set (γ0, γ1, γ2, γ3) as (1.2,−0.4, 0.2,−0.2) and (ω0, ω1, ω2) as (1.2, 0.2, 0.1). Then we categorized
Z into 10 groups, denoted by Zc, which takes integer values 1 to 10 for Z ∈ (0, 0.1), [0.1, 0.2), . . .,
[0.9, 1), respectively. The binary outcome Y was generated from the logistic regression model (3.1)
with Zc fitted instead of Z. In all three scenarios, the log OR parameters for (X1, X2, X3, X4, Zc)
were set to be the same and equal to (0.15, 0.2, 0.2, 0.6, 0.15). The log OR values for (X1, X2, X3, X4)
were set to be reasonably close to those in the existing model ϕ(s,x;η), since we wanted to have
similar association between standard predictors and the outcome in the case-control sample and
in the population. We chose different αs values so that the outcome prevalence in the three sce-
narios was 12.5%, 9.0%, and 9.8%, respectively. Above, we set up the covariate distribution and
outcome prevalence to be different from those in the population described in Step 1 to mimic the
differences between the BCDDP study, studies on validating the BCRAT, and national data as rep-
resented in SEER and NHIS. That is, the source population for the case-control sample differs
from the target population. The difference between the populations in the three scenarios and
that in Step 1 is depicted in Figure 3.2, where we plotted the “predicted” by model ϕ versus vs
the “observed” in each scenario. To do this, we first generated a large sample of size 107 based
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on the distribution of X and Z and P (Y |S,X, Z) specified above. Using the same partition of the
X space as that equivalent to asr <= ϕ(s,x;η) <= bsr in Step 1, we obtained the proportion
of cases in each of the subspaces (“observed”), denoted by P cc(Y = 1|ϕ(s,x;η)). Figure 3.2
plotted P cc(Y = 1|ϕ(s,x;η) ∈ [asr, bsr]), s = 1, 2, r = 1, 2, 3, 4 against the benchmark in (3.5),
P e(Y = 1|ϕ(s,x;η) ∈ [asr, bsr]), s = 1, 2, r = 1, 2, 3, 4. The “observed” vs “predicted” appeared to
differ appreciably in scenario 1 particularly for stratum 2 and be similar in scenarios 2 and 3. In all
the three scenarios, we first generated a cross-sectional sample of 40,000 subjects, among which
500 cases and 1000 controls for each stratum were selected into the case-control sample, that is, a
total of 1000 cases and 2000 controls were included in the analysis. We applied both the proposed
and “standard” methods, as described in the analysis of the BCDDP data, to analyze each of the
simulated datasets to estimate parameters (α,β,γ,ω). We repeated the simulation 1000 times.
The results for the three simulation scenarios were summarized in Tables 3.2, 3.3, and 3.4, re-
spectively. The “True” parameter values listed were for the source population of the case-control
sample, and the “Diff” was calculated as the difference between the estimates and their true val-
ues. Note that “Diff” is the estimation bias that is routinely used for assessing the consistency of
an estimator in finite samples. But we avoid the term “bias” because in our context, larger “Diff”
actually indicates that the constraints served to pull the estimates away from those obtained by the
standard method. Therefore, larger “Diff” implicates the effectiveness of our methods for pursusing
good calibration. The standard approach yielded largely unbiased estimates for all log ORs and
the distribution parameters for Z in all three scenarios as expected. In constrast, for the proposed
method, the averaged estimates of log OR for Zc and its distribution parameters were close to the
true parameter values. But the log OR estimates for predictors X varied across different scenarios.
For Scenarios 1 and 2, the Diff for (X1, X3, X4) was quite noticeable, especially for X3 where the
estimate was almost twice the true value. Two reasons might explain why the OR estimates for X
was affected by the contraints and for Z largely unchanged. First, as we enforced equality of the
calibration performance between the models with and without Z, the effects of X on Y would be
changed under Scenario 1 to accomodate the original large differences between the two as shown
in Figure 3.2. Second, different predictor distributions between the target and source populations
could also lead to changes in point estimates. Even though the “observed” and “expected” were
similar under Scenario 2, the difference in the X distribution resulted in biases for estimating the
correponding ORs. This similar reasoning can help explain results in Scenario 3, where our method
44
Figure 3.2: P e(Y = 1|ϕ(s,x;η)) versus P cc(Y = 1|ϕ(s,x;η)) under scenarios 1, 2, and 3. The
upper panel represents the results for stratum 1 with the 1st, 2nd, and 3rd risk quartiles equal to
2.5%, 4.1%, and 6.3%, respectively. The lower panel represents the results for stratum 2 with the
1st, 2nd, and 3rd risk quartiles equal to 6.6%, 10.4%, and 15.4%, respectively.
also yielded unbiased estimates of ORs for predictor X. Since neither the OR of Zc nor its distri-
bution were specified in the target population, heuristically, the inference of the related parameters
should be largely dominated by the case-control sample. As observed in the results, estimates by
the two methods were close in all three scenarios.
In all simulation scenarios, the averaged asymptotic standard error (“ASE) estimates were close
to the empirical standard errors (“SE”) for both methods under all three scenarios. For estimating
parameters related to Z, our method was more efficient than the standard approach with 15%
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reduction in the asymptotic variance for estimating the log OR and about 20% reduction on average
for estimating parameters in the Beta-regression model, (γ,ω). In Scenario 3 in which the efficiency
comparison of estimating βx was sensible, our method yielded more efficienct estimates especially
for X1 and X4, where the asymptotic variance reduced by more than 80%. The efficiency gains for
estimating (βz,γ,ω) were similar to those in the previous two scenarios.
Table 3.2: Estimation results under scenario 1. True: true parameter values; Est: mean estimates;
Diff (%): the differences between mean estimates and true values divided by true values; SE:
empirical standard error estimates; ASE: mean asymptotic standard error estimates;
Proposed Standard
Parameter True Est Diff (%) SE ASE Est Diff (%) SE ASE
α1 -5.5 -5.887 7.04 0.193 0.193 -5.727 4.13 0.229 0.230
α2 1.5 1.026 -31.60 0.021 0.022 1.072 -28.50 0.041 0.040
βx1 0.15 0.179 19.33 0.008 0.008 0.148 -1.33 0.035 0.035
βx2 0.2 0.207 3.50 0.055 0.053 0.198 -1.00 0.060 0.060
βx3 0.2 0.481 140.50 0.039 0.041 0.200 0.00 0.052 0.052
βx4 0.6 0.535 -10.83 0.018 0.017 0.601 0.17 0.051 0.051
βzc 0.15 0.146 -2.67 0.021 0.021 0.151 0.67 0.023 0.023
γ0 1.2 1.200 0.00 0.047 0.047 1.198 -0.17 0.052 0.053
γ1 -0.4 -0.418 4.50 0.038 0.037 -0.430 7.50 0.046 0.049
γ2 0.2 0.198 -1.00 0.017 0.017 0.197 -1.50 0.018 0.018
γ3 -0.2 -0.196 -2.00 0.023 0.023 -0.204 2.00 0.026 0.026
ω0 1.2 1.205 0.42 0.055 0.053 1.199 -0.08 0.060 0.058
ω1 0.2 0.193 -3.50 0.059 0.061 0.190 -5.00 0.061 0.062
ω2 0.1 0.100 0.00 0.035 0.034 0.100 0.00 0.039 0.040
Table 3.3: Estimation results under scenario 2. True: true parameter values; Est: mean estimates;
Diff (%): the differences between mean estimates and true values divided by true values; SE:
empirical standard error estimates; ASE: mean asymptotic standard error estimates;
Proposed Standard
Parameter True Est Diff (%) SE ASE Est Diff (%) SE ASE
α1 -5.8 -5.873 1.26 0.199 0.200 -5.721 -1.36 0.236 0.236
α2 1.4 1.031 -26.36 0.022 0.023 1.067 -23.79 0.042 0.041
βx1 0.15 0.175 16.67 0.008 0.008 0.152 1.33 0.036 0.036
βx2 0.2 0.218 9.00 0.054 0.052 0.200 0.00 0.061 0.062
βx3 0.2 0.442 121.00 0.044 0.045 0.196 -2.00 0.052 0.052
βx4 0.6 0.548 -8.67 0.019 0.019 0.602 0.33 0.052 0.052
βzc 0.15 0.146 -2.67 0.022 0.021 0.149 -0.67 0.023 0.023
γ0 1.2 1.200 0.00 0.047 0.045 1.196 -0.33 0.052 0.052
γ1 -0.4 -0.406 1.50 0.040 0.039 -0.410 4.75 0.045 0.046
γ2 0.2 0.199 -0.50 0.017 0.017 0.198 -1.00 0.019 0.019
γ3 -0.2 -0.196 -2.00 0.023 0.023 -0.202 1.00 0.026 0.026
ω0 1.2 1.203 0.25 0.054 0.055 1.196 -0.33 0.059 0.060
ω1 0.2 0.196 -2.00 0.058 0.055 0.196 -2.00 0.060 0.058
ω2 0.1 0.101 1.00 0.036 0.038 0.101 2.00 0.040 0.041
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Table 3.4: Estimation results under scenario 3. True: true parameter values; Est: mean estimates;
Diff (%): the differences between mean estimates and true values divided by true values; SE:
empirical standard error estimates; ASE: mean asymptotic standard error estimates;
Proposed Standard
Parameter True Est Diff (%) SE ASE Est Diff (%) SE ASE
α1 -5.8 -5.792 -0.14 0.208 0.210 -5.729 -1.22 0.248 0.247
α2 1.4 1.150 -17.86 0.022 0.022 1.226 -12.43 0.039 0.040
βx1 0.15 0.156 4.00 0.007 0.007 0.149 -0.67 0.038 0.038
βx2 0.2 0.192 -4.00 0.060 0.058 0.202 1.00 0.065 0.064
βx3 0.2 0.207 3.50 0.052 0.054 0.202 1.00 0.056 0.056
βx4 0.6 0.638 6.33 0.019 0.019 0.599 -0.17 0.054 0.054
βzc 0.15 0.151 0.67 0.023 0.023 0.151 0.67 0.025 0.025
γ0 1.2 1.204 0.33 0.047 0.047 1.197 -0.25 0.051 0.052
γ1 -0.4 -0.411 2.75 0.041 0.038 -0.422 5.50 0.047 0.050
γ2 0.2 0.201 0.50 0.017 0.017 0.198 -1.00 0.019 0.019
γ3 -0.2 -0.201 0.50 0.025 0.025 -0.204 2.00 0.027 0.028
ω0 1.2 1.200 0.00 0.063 0.062 1.197 -0.25 0.071 0.071
ω1 0.2 0.202 1.00 0.065 0.064 0.196 -2.00 0.067 0.067
ω2 0.1 0.101 1.00 0.043 0.044 0.100 0.00 0.048 0.049
3.5. Conclusion
Our method offers a way to exploit existing models for the development of new models that in-
coporate new predictors. Through suitable constraints for maximizing the likelihood function, our
proposed method can yield a model that is calibrated similarly as the existing model, but it does
not enforce that the model expanded with the biomarkers has to be the “true model” in the source
population of the data. For predicting human diseases, the interest is often on identification of pop-
ulation subgroups who have high, or sometimes low, risk. Therefore, it is important that the model
has good calibration in the tails of the risk distribution. Our method achieves this goal by setting
up suitable constraints in our method. On the other hand, we put as loose constraints as possible
on the predicted risk in the subgroup with moderate risk, which to a large extent allows the data
to inform the relationship between the outcome, standard predictors, and biomarkers. When the
data is collected under the case-control study design, such constraints can just be the outcome
prevalence in that subgroup, which is necessary for estimating the intercept parameter in the logis-
tic prediction model. To compare the impact of different constraints on the model developed, we
also analyzed BCDDP data with eight constraints similarly as in Section 3, but with the BCRAT risk
cutoff points placed at the (25%, 75%) percentiles for the stratum of age ≤ 50 and (15%, 25%,
75%, 85%) percentiles for the stratum of age > 50. The OR estimates for the BCRAT predictors
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can be quite different (Appendices). It is also computationally advantageous to place constraints
in the risk groups that are of primary interest, since we found that too many constraints may lead
to numerical problems. Of course, our method ensures good calibration only in population strata
defined by standard predictors. It is ideal that the new model with biomarkers incorporated can be
validated in a suitable cohort where data on standard predictors and biomarkers is available.
One limitation of our approach is that a parametric model is needed to relate biomarkers to standard
predictors. Mis-specification of this model may negatively affect the calibration of the new model.
For many human diseases which are rare, careful model selection can be performed using data
from controls. It may also be helpful to explore more flexible model forms. When multiple biomarkers
are involved, it is challenging to specify a parametric model, and it is largely infeasible to leave the
biomarker distribution nonparametrically due to the curse of dimensionality. Extension of our work
by relaxing the parametric distribution requirement is warranteed.
Our method particularly allows that the source and target populations can differ. As seen in the
BCDDP, the BCDDP women and the general Caucasian women differed in the composite breast
cancer rates and also breast cancer risk factor distributions. The BCRAT assumed that the odds
ratio function for breast cancer was the same in the BCDDP and general Caucasian woman popu-
lation. When the target population is well characterized and a prediction model exists, our method
offers a way to develop a practical model using a data source that may deviate from the target
population while ensuring desirable calibration. In the current work, we assumed that no informa-
tion was available on the relationship between biomarkers and standard predictors. For biomarker
discovery, it is frequent that the relationship between biomarkers and standard predictors is studied
first, particularly when the outcome data is not readily available. It might be sensible to incorpo-
rate such established relationship into the model development by modifying the constraints that we
exploited. Alternatively, it may make better sense to recognize that such relationship in the target
population may better be approximated as an average of the external relationship and that relation-
ship reflected in the case-control sample. We will investigate the feasibility of extending our method
along these lines.
We analyzed a subset of the BCDDP cases and controls to demonstrate our methods, where the
remaining subjects were excluded due to the lack of mammographic density data. The analysis was
valid because the availability of mammograms only depended on the case-control status (Chen et
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al., 2006). However, the efficiency can be enhanced if data on the BCRAT predictors for those
excluded can be incorporated into the analysis. We will extend our method to accommodate the
incomplete data in the future work.
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CHAPTER 4
A SEMIPARAMETRIC APPROACH TO DEVELOPING WELL-CALIBRATED MODELS
FOR PREDICTING THE RISK OF BINARY OUTCOMES USING CROSS-SECTIONAL
DATA
50
4.1. Introduction
In this chapter, we extend the statistical methods developed in Chapter 3 to accommodate the
cross-sectional studies, which often can not be treated as a random sample selected from the
target population. We consider the same scenario where a well-calibrated model based on standard
predictors exists, and the goal is to incorporate the new risk predictors into the existing model. We
assume that data on the outcome and all predictors is available from a cross-sectional sample.
We adopt the constrained maximum likelihood method proposed in Chapter 3, which guarantees
that the new model calibrates similarly as the existing model, allows the distribution of standard
risk predictors in the sample to be different from that in the target population of prediction, and
relies on the data to infer the relationship between biomarkers and standard predictors. This work
is actually motivated by the study of Gestational Diabetes Mellitus as described in Chapter 2 (Zhu
et al., 2016). The Phase I sample in the study can be seen as a prospective cohort study, where
data on the outcome and predictors including age, race, BMI and family history was measured for
all study subjects. The distribution of age, race and BMI was externally available in the National
Vital Statistics Report from Centers for Disease Control and Prevention (CDC), which turned out
to be quite different from that in the data. Given that the information of the relationship between
family history and these predictors was limited or unknown, we formulated the problem into our
constrained MLE approach framework by treating family history as the “new” predictor. The goal
was to develop a model with all four predictors included and the model was calibrated to an existing
model based on age, race and BMI, where the latter was available in previous literature (Berkowitz
et al., 1992; Solomon et al., 1997).
The differences of this work from what has been done in the previous chapter are listed here.
First, there is no profile likelihood when deriving the objective function for our method because
the empirical distribution of standard risk predictors will be totally factored out and irrelavent in
the likelihood function in terms of estimating the association parameters. Second, the intercept
term can be directly estimated via fitting a logistic regression model to the data under the standard
approach, which is used for the comparison purpose. Lastly, the standard approach can use both
cases and controls to estimate the distribution parameters for biomarkers because of the cross-
sectional study designs.
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The rest of this Chapter is organized as follows. We describe our proposed method and inference
procedures in Section 4.2. In Section 4.3, we assess the finite sample performance of our method
using simulated data, considering small or large differences between the data and the target pop-
ulation and statistical efficiency. In Section 4.4, we will apply our method to analyze the Phase I
data of National Institute of Child Health and Human Development (NICHD) Fetal Growth Study
Singletons to develop a logistic regression model for predicting the risk of gestational diabetes.
4.2. The Method
4.2.1. Notation and likelihood function
We consider a cross-sectional sample of size N , where the standard risk predictors and biomarkers
are measured, denoted by X and Z, respectively. Let Y represent the disease status with Y = 1
indicating cases and Y = 0 indicating controls. We use a logistic regression model to predict Y
based on (X,Z):
P (Y = y|x, z) = exp{y(α+ β
T
x x + β
T
z z)}
1 + exp{α+ βTx x + βTz z}
, y = 0, 1 (4.1)
where (βx,βz) are the log odds ratios for (X,Z). We use a parametric model fτ (z|x) with Euclidean
parameters τ to describe the conditional distribution of Z|X. Let Pyxz ≡ P (Y = y|X = x,Z =
z), y = 0, 1. The empirical log-likelihood function of the sample can be derived as
l(α,β, τ ) = log
N∏
i=1
P (Yi = yi,Xi = xi,Zi = zi)
= log
N∏
i=1
P (Yi = yi|Xi = xi,Zi = zi)P (Xi = xi)P (Zi = zi|Xi = xi)
∝
N∑
i=1
logP (yi|xi, zi) +
N∑
i=1
log fτ (zi|xi)
where β = (βx,βz). The log-likelihood function is much simpler than that for the case-control data,
since we can factor out the empirical distribution of X because it doesn’t involve (α,β). We assume
that a well-calibrated risk prediction model based on X is available and well-calibrated for strata
defined by X, and we use ϕ(X) to represent the corresponding predicted risk. The distribution of X
in the target population of prediction, P e(X), is known from external sources, where the superscript
“e” here and after indicates “external”. We explicitly allow P e(X) to be different from that in the
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data. We categorize predicted risk ϕ into I intervals and use ar and br to denote the beginning and
end of each interval. We assume that the calibration of the model ϕ(X) was evaluated in external
studies by comparing the averaged predicted risk within each interval, defined as
P e(Y = 1|ar ≤ ϕ(x) ≤ br), r = 1, ..., I,
with the “observed” averaged risk. We impose the equality of these averaged risks between the
newly developed model (4.1) and ϕ(X) to ensure a good calibration performance of the new model.
The resultant constraints are expressed as below:
P e(Y = 1|ar ≤ ϕ(x) ≤ br) =
∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
, r = 1, ..., I. (4.2)
4.2.2. Constrained maximum likelihood for estimating (α,β, τ )
We apply the similar approach as developed in the previous chapter, i.e., maximize the log-likelihood
function l(α,β, τ ) subject to the constraint (4.2). The objective function using Lagrange multipliers
λ = (λr : r = 1, ..., I) is written as
g(α,β, τ ,λ) = l(α,β, τ )
+
I∑
r=1
λr
{∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
− P e(Y = 1|ar ≤ ϕ(x) ≤ br)
}
. (4.3)
To maximize the above function with respect to all unknown parameters, we derive the correspond-
ing score functions by taking the first derivative of g(α,β, τ ,λ) with respect to (α,β, τ ,λ), respec-
tively. The score functions are denoted by {Sα, Sβ, Sτ , Sλ} and the maximum likelihood estimates
(α̂, β̂, τ̂ , λ̂) are obtained via solving
{
STα , S
T
β , S
T
τ , S
T
λ
}T
= 0. The details are provided in the Ap-
pendices.
4.2.3. Identifiability, consistency and asymptotic normality
The theorems developed in Chapter 3 for case-control data can be applied in this cross-sectional
data setting.
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4.3. Simulation Studies
We conducted extensive simulation studies to evaluate the finite sample performance of our pro-
posed methods. To make clear distinction between the target population of prediction and the
cross-sectional sample, we set up the simulation scheme in two steps. First, we defined a popula-
tion where the true distribution of X, P e(X), was known, and a well-calibrated risk prediction model
based on X was available. Second, we generated data for the established risk predictors X and
biomarker Z for a cross-sectional sample.
4.3.1. Step 1: Define P e(X) and ϕ(X)
We considered three standard predictors X = (X1, X2, X3), where X1 ∼ N(30, 5) was categorized
into 5 groups by ≤ 25, (25, 30], (30, 35], (35, 40] or > 40, X2 was generated from a Multinomial
distribution with probabilities (0.3, 0.2, 0.2, 0.3), and X3 ∼ Poisson(25) was categorized into 6
groups by ≤ 20, (20, 25], (25, 30], (30, 35], (35, 40] or > 40. The three predictors were mutually
independent, thus their joint distribution, P e(X), can be expressed as
∏3
i=1 P
e(Xi), which was
treated as known. We assumed that the following logistic regression model for predicting the risk
of Y based on X, where X1 and X3 were fitted as ordinal while X2 was a categorical variable, was
well calibrated:
ϕ(x;η) ≡ pe(Y = 1|x;η) = exp(η0 + η1x1 + η2
Tx∗2 + η3x3)
1 + exp(η0 + η1x1 + η2Tx
∗
2 + η3x3)
,
where x∗2 was a vector of indicator functions with length 3 that represented x2. We set the parame-
ters (η0, η1,η2, η3) to be (-5, 0.25, 0.5, 0.5, 0.5, 0.5) so that the disease prevalence of Y , P (Y = 1),
was around 6.5%. Consistent with the common goodness-of-fit test of calibration, we chose the
quartiles of ϕ(x;η) as the risk cutoff values used in the constraints (4.2). Together with P e(X), we
were able to calculate the averaged risk within each interval [ar, br], r = 1, 2, 3, 4 as
P e(Y = 1|ϕ(x;η) ∈ [a, b]) = (2.5%, 4.2%, 6.7%, 12.2%). (4.4)
These four numbers were considered as the calibration benchmark, leading to four corresponding
constraints as described in (4.2).
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4.3.2. Step 2: Generate the Cross-Sectional Sample Data
We considered two scenarios. In the first scenario, we generated X from distributions that were
different from those in Step 1 by using different parameter values. X1 ∼ N(33, 5),X2 was generated
from a Multinomial distribution with probabilities (0.25, 0.25, 0.25, 0.25), and X3 from a Poisson
distribution with mean 28. All three variables were coded the same way as in Step 1. In the second
scenario, X followed the same distribution as that in Step 1. We considered a single biomarker Z
with two values 1 or 0 that followed the logistic regression model,
logitP (Z = 1|x1, x3) = τ0 + τ1x1 + τ2x3.
We set (τ0, τ1, τ2) as (-2, 0.2, 0.2). The binary outcome Y was generated from the logistic regression
model (4.1), and the log OR parameters for (X1,X∗2, X3, Z) were set to be the same under the two
scenarios and equal to (0.2, 0.45, 0.45, 0.55, 0.55, 0.5). The log OR values for (X1,X∗2, X3) were
set to be reasonably close to those in the existing model ϕ(x;η), since we wanted to maintain
the association between standard predictors and the disease in the sample and in the population.
We chose different α values so that the disease prevalence in the two scenarios was 11.5% and
7.0%, respectively. Under scenario 1, we set up the covariate distribution and outcome prevalence
to be different from those in the population described in Step 1 to mimic the differences between
the GDM study and the national data as represented in CDC. That is, the prospective cohort study
differs from the target population. The difference between the populations in the two scenarios and
that in Step 1 is depicted in Figure 4.1, where we plotted the “predicted” by model ϕ versus vs the
“observed” in each scenario. To do this, we first generated a large sample of size 107 based on the
distribution of X and Z and P (Y |X, Z) specified above. Using the same partition of the X space as
that equivalent to ar <= ϕ(x;η) <= br in Step 1, we obtained the proportion of cases in each of the
subspaces (“observed”), denoted by P cc(Y = 1|ϕ(x;η)). Figure 4.1 plotted P cc(Y = 1|ϕ(x;η) ∈
[ar, br]), r = 1, 2, 3, 4 against the benchmark in (4.4), P e(Y = 1|ϕ(x;η) ∈ [ar, br]), r = 1, 2, 3, 4. The
“observed” vs “predicted” appeared to differ appreciably in scenario 1 while be similar in scenarios
2. In both scenarios, we generated 5,000 subjects for the analysis. We applied both the proposed
and “standard” methods, as described in the analysis of the GDM data, to analyze each of the
simulated datasets to estimate parameters (α,β, τ ). We repeated the simulation 1000 times.
55
Figure 4.1: P e(Y = 1|ϕ(x;η)) versus P cc(Y = 1|ϕ(x;η)) under scenarios 1 and 2 with the 1st, 2nd,
and 3rd risk quartiles equal to 3.7%, 6.0%, and 7.6%, respectively.
The results for the two simulation scenarios were summarized in Tables 4.1 and Table 4.2, respec-
tively. The “True” parameter values listed were for the cross-sectional sample, and the “Diff” was
calculated as the difference between the estimates and their true values. Note that “Diff” is the
estimation bias that is routinely used for assessing the consistency of an estimator in finite sam-
ples. But we avoided the term “bias” because in our context, larger “Diff” actually indicated that
the constraints served to pull the estimates away from those obtained by the standard method.
Therefore, larger “Diff” implicated the effectiveness of our methods for pursuing good calibration.
The standard approach yielded largely unbiased estimates for all log ORs and the distribution pa-
rameters for Z in both scenarios as expected. In constrast, for the proposed method, the averaged
estimates of log OR for Z and its distribution parameters were close to the true parameter values.
But the log OR estimates for predictors X varied across different scenarios. For Scenarios 1, the
Diff for (X1,X∗2, X3) was quite noticeable. Two reasons might explain why the OR estimates for X
was affected by the contraints and for Z largely unchanged. First, as we enforced equality of the
calibration performance between the models with and without Z, the effects of X on Y would be
changed under Scenario 1 to accomodate the original large differences between the two as shown
in Figure 4.1. Second, different predictor distributions between the target population and the data
could also lead to changes in point estimates. On the other hand, under Scenario 2 where the
“observed” and “expected” risks were similar and P (X) was the same between the data and the
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Table 4.1: Estimation results under scenario 1. True: true parameter values; Est: mean estimates;
Diff (%): the differences between mean estimates and true values divided by true values; SE:
empirical standard error estimates; ASE: mean asymptotic standard error estimates;
Proposed Standard
Parameter True Est Diff (%) SE ASE Est Diff (%) SE ASE
α -5 -4.982 -0.36 0.080 0.079 -5.170 3.40 0.192 0.193
βx1 0.2 0.222 11.00 0.040 0.040 0.199 -0.50 0.047 0.046
βx21 0.45 0.361 -19.78 0.134 0.132 0.448 -0.44 0.139 0.139
βx22 0.45 0.363 -19.33 0.133 0.132 0.450 0.00 0.138 0.139
βx23 0.55 0.381 -30.73 0.128 0.128 0.551 0.18 0.134 0.135
βx3 0.55 0.495 -10.00 0.021 0.022 0.551 0.18 0.042 0.042
βz 0.5 0.496 -0.80 0.091 0.092 0.497 -0.60 0.091 0.092
τ0 -2 -1.998 -0.10 0.136 0.136 -2.007 0.35 0.137 0.136
τ1 0.2 0.202 1.00 0.031 0.031 0.202 1.00 0.031 0.031
τ2 0.2 0.194 -3.00 0.029 0.029 0.200 0.00 0.029 0.030
population, our method yielded almost unbiased estimates of ORs for predictor X. Since neither
the OR of Z nor its distribution were specified in the target population, heuristically, the inference of
the related parameters should be largely dominated by the data itself. As observed in the results,
estimates by the two methods were close in both scenarios.
In the two simulation scenarios, the averaged asymptotic standard error (“ASE) estimates were
close to the empirical standard errors (“SE”) for both methods. For estimating parameters related to
Z, the standard approach was as efficient as our method for estimating (βz, τ ). Unlike the standard
approach in Chapter 3 where only controls could be used to estimate the distribution parameters
for biomarkers, both cases and controls were used for the estimation in current work because of
the cross-sectional study design. In Scenario 2 where the efficiency comparison of estimating βx
was sensible, our method yielded more efficienct estimates especially for X3, where the asymptotic
variance reduced by more than 70%.
4.4. The Analysis of a Study of Gestational Diabetes Mellitus
Using Phase I data (as described in Chapter 2) from the National Institute of Child Health and
Human Development (NICHD) Fetal Growth Study Singletons, we applied our proposed methods
to build a logistic regression model for predicting the risk of gestational diabetes mellitus (GDM).
In this prospective study cohort (Zhu et al., 2016), data on age, race, body mass index, and family
history of diabetes was fully collected for 2,799 women. In the model, we considered 5-year age
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Table 4.2: Estimation results under scenario 2. True: true parameter values; Est: mean estimates;
Diff (%): the differences between mean estimates and true values divided by true values; SE:
empirical standard error estimates; ASE: mean asymptotic standard error estimates;
Proposed Standard
Parameter True Est Diff (%) SE ASE Est Diff (%) SE ASE
α -5.1 -4.964 -2.67 0.102 0.098 -5.177 1.51 0.238 0.239
βx1 0.2 0.187 -6.50 0.052 0.052 0.200 0.00 0.057 0.057
βx21 0.45 0.423 -6.00 0.169 0.167 0.457 1.56 0.173 0.174
βx22 0.45 0.425 -5.56 0.164 0.165 0.459 2.00 0.172 0.172
βx23 0.55 0.526 -4.36 0.150 0.150 0.560 1.82 0.156 0.157
βx3 0.55 0.515 -6.36 0.027 0.026 0.550 0.00 0.055 0.055
βz 0.5 0.501 0.20 0.120 0.121 0.501 0.20 0.120 0.122
τ0 -2 -1.995 -0.25 0.123 0.123 -2.002 0.10 0.123 0.123
τ1 0.2 0.200 0.00 0.033 0.034 0.201 0.50 0.033 0.033
τ2 0.2 0.197 -1.50 0.033 0.032 0.199 -0.50 0.033 0.032
intervals and fitted them as ordinal variable after exploring their functional forms by local polynomial
regression. BMI (kg/m2) was categorized into three groups as normal if the value was from 18.5 to
25, overweight if 25 to 30, and obese if over 30, and fitted as categorical variable. Both race (White,
Black, Hispanic, Asian) and family history (Yes or No) were fitted as categorical variables as well.
To ensure a good calibration performance of our model, i.e., to accurately predict the expected
number of GDM cases in defined population subgroups, we imposed the constraints based on the
results published in Berkowitz et al. (1992) and Solomon et al. (1997). In their work, the association
between (Age, Race, BMI) and gestational diabetes has been well studied with large cohort data
using logistic regression models. We assumed that the model based on X = (Age, Race, BMI)
with log ORs reported in these paper to be well-calibrated. Let ϕ(X) denote the corresponding
predicted risk and the expression was provided as below
ϕ(x) = P e(Y = 1|x)
=
exp{η0 + η1Age∗ + η2Black + η3Hispanic+ η4Asian+ η5Overweight+ η6Obese}
1 + exp{η0 + η1Age∗ + η2Black + η3Hispanic+ η4Asian+ η5Overweight+ η6Obese} ,
where Age∗ represented the recoded 5-year age intervals and (η1, η2, η3, η4, η5, η6) reported by
Berkowitz et al. (1992) and Solomon et al. (1997) was equal to log(1.63), log(1.75), log(1.45),
log(2.32), log(2.13), log(2.90), respectively. Given the disease prevalence of 4% reported in liter-
ature, we were able to recover the intercept term η0. By equating the prediction performance of our
new model which also included Z = family history, which was treated as biomarker in this analysis,
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to that of ϕ(X), we would successfully maintain the “well-calibration” property. Moreover, the dis-
tribution of X, P e(X), was externally available from the National Vital Statistics Reports (NVSR) of
Centers for Disease Control and Prevention (CDC). Due to the limited knowledge of the population-
level distribution of family history at different ages and BMI values in different race groups, we
proposed to model f(Z|X) via a logistic regression model. Implicitly, we assumed f(Z|X) to be
the same in the data and in the general population. Based on ϕ(X) and P e(X), we were able to
calculate P e(Y = 1|ar ≤ ϕ(x) ≤ br). We considered two sets of [ar, br] values, where the first set
was equal to the quartiles of ϕ(X) while the second set was equal to the (15%, 25%, 75%, 85%)
percentiles. Note that the latter imposed much finer constraints on the tails of the risk distribution,
i.e., subjects classified as low or high risk were given more weights. The calculated averaged risks
within each set were summarized as below
P e(Y = 1|ϕ(x) ∈ [a1, b1]) = (1.3%, 3.2%, 5.6%, 11.0%),
P e(Y = 1|ϕ(x) ∈ [a2, b2]) = (1.1%, 1.9%, 4.2%, 9.2%, 12.8%).
We used these numbers as the benchmark for risk prediction calibration and the resultant con-
straints were expressed as in (4.2). Again, we compared our proposed constrained maximum
likelihood method to a “standard” approach, where two logistic regression models were fitted to the
data. The first one was to estimate the OR parameters in the risk prediction model and the sec-
ond one was to estimate the distribution parameters for family history. The stanard error estimates
for the standard approach were calculated using stantard MLE approach. Unlike the “standard”
approach for case-control data, we were able to directly estimate the intercept parameter and use
both cases and controls to estimate the distribution parameters for family history because of the
non-retrospective nature of the data.
The results were summarized in Table 4.3. Older age, higher BMI and positive family history of dia-
betes appeared to be positively associated with the risk of gestational diabetes. Asian and Hispanic
women had a higher chance of developing GDM than White women, while Black women were not
statistically significant different from White women. However, the estimated log ORs obtained by our
method for risk predictors could be quite different from those by the standard method. When using
the quartiles of ϕ(X) as the risk cutoff points in the constraints, the estimate for age was 0.5 times
larger while the estimates for Asian, Overweight and Obese were smaller. Because our method
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assumed the same model relating the risk of GDM with predictors in the general population and the
data, these differences might indicate the effectiveness of our method for pursuing good calibra-
tion. We conjectured that the differences in the standard predictors distribution, P (X), between the
data and the NVSR largely drove the discrepancy in the OR estimates. As shown in Table 4.4, the
distribution of age and race differed substantially from the reported estimates in NVSR while the
distribution of BMI was reasonably different from that in NVSR. We noticed that different constraints
impacted differently on the log OR estimates for X. Using (15%, 25%, 75%, 85%) percentiles of
ϕ(X) as the cutoffs, cMLE2 yielded smaller log OR estimate for age than cMLE1 but still larger
than the standard approach. For race, cMLE2 yielded larger estimates for Asian women than the
standard approach, while cMLE1 was the opposite. Since the new contraints were more focused
on women classified as low or high risk instead of women with moderate risk, the log OR estimates
would be changed accordingly to accomodate the different association effects between X and Y in
these “extreme” groups. With regard to family history, both the estimates of log OR and distribution
parameters were similar across the three approaches. Our assumption of the same distribution of
family history in the population and in the data might explain these consistencies. In the logistic
regression model for family history, all predictors were significant and positively associated with the
probability of having a positive family history. In terms of statistical efficiency, our approach with
either type of constraints yielded more efficient log OR estimates for X compared to the standard
method, with more than 80% efficient gains for intercept, age and obese and more than 40% for the
remainings. On the other hand, the standard errors for the log OR estimate of family history and
its distribution parameters estimates were similar between our method and the standard approach
because the latter was able to use both cases and controls for the estimation due to the prospective
nature of the data.
4.5. Conclusion
Our proposed method offers a way to exploit the existing models for the development of new mod-
els that incorporate new predictors. By calibrating the newly developed model to the existing model
through suitable constraints, our approach achieves similar calibration performance, but it doesn’t
enforce that the expanded model has to be the “true” model in the cross-sectional study. We also
explore the effect of different types of constraints on the odds ratio estimates in the logistic re-
gression model developed. In the analysis of GDM, we first impose the constraints based on the
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Table 4.3: Analysis of Gestational Diabetes Mellitus data: estimates of intercept term and log
ORs for 5-year age intervals, race, BMI and family history, together with estimates of parameters
in the logistic regression model for the distribution of family history. In the paranthesis are the
corresponding estimates of asymptotic standard errors; “cMLE1” represents estimates from the
proposed constrained maximum likelihood method when using quartiles of ϕ(x) as a′s and b′s in
the constraints; “cMLE2” represents estimates from the proposed constrained maximum likelihood
method when using (15%, 25%, 75%, 85%) percentiles of ϕ(x) as a′s and b′s in the constraints;
“Standard” represents the estimates from the standard approach.
cMLE1 cMLE2 Standard
Predictors
Intercept -5.810 (0.064) -5.529 (0.059) -5.300 (0.442)
Age∗ 0.522 (0.020) 0.419 (0.027) 0.339 (0.098)
Black -0.381 (0.290) -0.103 (0.133) -0.539 (0.352)
Hispanic 0.484 (0.216) 0.640 (0.150) 0.447 (0.274)
Asian 0.592 (0.237) 0.779 (0.238) 0.692 (0.319)
Overweight 0.599 (0.190) 0.601 (0.183) 0.805 (0.261)
Obese 1.175 (0.104) 1.202 (0.104) 1.435 (0.274)
Family history 0.581 (0.218) 0.602 (0.210) 0.585 (0.220)
Intercept -2.590 (0.193) -2.618 (0.192) -2.574 (0.193)
Age∗ 0.191 (0.044) 0.197 (0.044) 0.187 (0.044)
Family history Black 0.542 (0.143) 0.557 (0.143) 0.536 (0.143)
Model Hispanic 0.678 (0.136) 0.690 (0.136) 0.675 (0.137)
Asian 0.692 (0.155) 0.704 (0.155) 0.692 (0.155)
Overweight 0.348 (0.114) 0.352 (0.114) 0.351 (0.114)
Obese 0.699 (0.128) 0.709 (0.128) 0.703 (0.128)
Table 4.4: Distribution of age, race and BMI for pregnant women estimated in the Gestational
Diabetes Mellitus data and reported in the National Vital Statistics Report (NVSR).
GDM data NVSR
(15, 20) 10.1% 19.6%
[20, 25) 23.5% 20.8%
Age [25, 30) 31.2% 20.5%
[30, 35) 25.1% 20.1%
[35, 40] 10.1% 19.0%
White 26.8% 63.1%
Race Black 27.8% 13.4%
Hispanic 28.8% 17.2%
Asian 16.6% 6.3%
Normal 56.5% 51.2%
BMI Overweight 26.5% 24.9%
Obese 17.0% 23.9%
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quartiles of the risk distribution from external model, i.e., we divide the group of interests evenly
according to their predicted risks. Second, we place finer constraints on the tails of the risk distri-
bution while cruder constraints in the middle, i.e., we focus more on the group with higher or lower
risk and less on the group with moderate risk. Due to the numerical problems caused by too many
constraints, we might prefer to put constraints in the risk groups that are of primary interest.
Our approach also explicitly allows the distribution of standard risk predictors to be different between
the cross-sectional study and the target population of prediction. As seen in the GDM data, the
distribution of race and 5-year age intervals differed substantially from that estimated in the National
Vital Statistics Report. Our method provides a practical way of integrating data sources that may be
different from each other while ensuring desirable calibration performance. On the other hand, we
relies on the data itself to infer the relationship between biomarkers and the standard predictors.
We use a parametric model to relate the two and one limitation of this approach is model mis-
specification, which might negatively affect the calibration performance of our model. Therefore, it
might be attractive to relax the parametric assumption and adopt more flexible model forms. For
biomarker discovery, the relationship between biomarkers and standard risk predictors is always
studied first, which makes it sensible to incorporte this knowledge into our model development via
constraints. We will investigate the feasibility of extending our method along these lines.
There are two main differences between applying our appoach to a cross-sectional study and ap-
plying it to a case-control study. First, the likelihood function of a cross-sectional study is straight-
forward and simpler than that of a case-control study, because the empirical distribution of standard
predictors is irrelavent during the estimation process for the former, but has to be factored out via
profile likelihood approach for the latter. Second, in term of the statistical efficiency of estimating
the distribution parameters of biomarkers, our method is as efficient as the standard approach for
analyzing a cross-sectional study while is more efficient for analyzing a case-control study. This
is because the current sampling scheme allows the standard method to use both cases and con-
trols to estimate the distribution of biomarkers. On the contrary, the standard method can only use
controls for the estimation in a case-control study and thereby lose the efficiency.
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CHAPTER 5
DISCUSSION
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In this dissertation, we developed an arsenal of statistical methods to address the statistical chal-
lenges in developing and validating models for predicting binary outcomes when the biomarkers
have limited availability. We first proposed three approaches, known as semiparametric maxi-
mum likelihood, pseudo-likelihood and weighted likelihood, to estimating the risk distribution and
summary measures of predictive accuracy under two-phase studies. We also developed a novel
sampling strategy for selecting Phase II subjects based on a preliminary model that included only
Phase I predictors to improve the efficiency of estimating the predictive accuracy measures. We
then applied the proposed methods and sampling strategy to develop and evaluate a risk predic-
tion model for Gestational Diabetes Mellitus. Later, motivated by the lack of independent data to
validate biomarkers for prediciotn, we incorporated the external knowledge of the distribution of
standard risk predictors and a known well-calibrated model built on them in the target population
of prediction, and proposed a novel constrained maximum likelihood approach to develop a model
that guaranteed the good calibration performance. We applied the proposed statistical methods to
both case-control studies and cross-sectional studies. With the application to a case-control study
nested in BCDDP to evaluate the added value of percent mammographic density on breast cancer
risk prediction and an ongoing prospective study of Gestational Diabetes, respectively, we demon-
strated that our approach ensured good calibration performance and yielded more efficient odds
ratio estimates.
These methods although have their own limitations as described in each chapter, they are readily
applicable to binary outcome risk prediction problems when new predictors have missing data,
or developing a well-calibrated model when there was lack of independent data to validate the
biomarkers for prediction and external information of established predictors is available.
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APPENDIX A
THEORETICAL DERIVATIONS
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A.1. Chapter 2
A.1.1. Estimators of PCF under PL, and estimators of PNF and AUC under ML, PL and WL meth-
ods
P̂CFq(θˆPL, FˆPL) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p1(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ξq}p1(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)
 ,
where ξq is defined by equation
q =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ξq}
N
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)
.
P̂NFp(θˆML, FˆML) =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ξp}
N
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
,
where ξp is defined by equation
p =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ξp}p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
 .
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P̂NFp(θˆPL, FˆPL) =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ξp}
N
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)
,
where ξp is defined by equation
p =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p1(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ξp}p1(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)
 .
P̂NFp(θˆWL, FˆWL) =
1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys I{p(xysk, zysk; θˆWL) > ξp},
where ξp is defined by equation
p =
∑1
y=0
∑S
s=1
∑Nys
k=1Ryskpˆi
−1
ys I{p1(xysk, zysk; θˆWL) > ξp}p1(xysk, zysk; θˆWL)∑1
y=0
∑S
s=1
∑Nys
k=1Ryskpˆi
−1
ys p1(xysk, zysk; θˆWL)
.
ÂUC(θˆML, FˆML) =
∫
T̂PRν(θˆML, FˆML)d{F̂PRν(θˆML, FˆML)},
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where
T̂PRν(θˆML, FˆML) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ν}p1(xysk, zysk; θˆML)
1∑
y=0
µˆyspy(xysk, zysk; θˆML)

and
F̂PRν(θˆML,FˆML) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
{1− p1(xysk, zysk; θˆML)}
1∑
y=0
µˆyspy(xysk, zysk; θˆML)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆML) > ν}
{
1− p1(xysk, zysk; θˆML)
}
1∑
y=0
µˆyspy(xysk, zysk; θˆML)
 .
ÂUC(θˆPL, FˆPL) =
∫
T̂PRν(θˆPL, FˆPL)d{F̂PRν(θˆPL, FˆPL)},
where
T̂PRν(θˆPL, FˆPL) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
p(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ν}p1(xysk, zysk; θˆPL)
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)

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and
F̂PRν(θˆPL, FˆPL) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
{1− p1(xysk, zysk; θˆPL)}
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
I{p1(xysk, zysk; θˆPL) > ν}
{
1− p1(xysk, zysk; θˆPL)
}
1∑
y=0
pˆiyspy(xysk, zysk; θˆPL)
 .
ÂUC(θˆWL, FˆWL) =
∫
T̂PRν(θˆWL, FˆWL)d{F̂PRν(θˆWL, FˆWL)},
where
T̂PRν(θˆWL, FˆWL) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys p1(xysk, zysk; θˆWL)

−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys I{p(xysk, zysk; θˆWL) > ν}p1(xysk, zysk; θˆWL)

and
F̂PRν(θˆWL,FˆWL) =

1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys
{
1− p1(xysk, zysk; θˆWL)
}
−1
×

1∑
y=0
S∑
s=1
Nys∑
k=1
Ryskpˆi
−1
ys I{p1(xysk, zysk; θˆWL) > ν}
{
1− p(xysk, zysk; θˆWL)
} .
A.1.2. Large Sample Theories for the Proposed Estimators of Predictive Accuracy Measures
For ML, PL and WL methods, recall that we write the estimated predictive accuray statistics as
TˆML = T{θˆML, FˆML(θˆML)}, TˆPL = T{θˆPL, FˆPL(θˆPL, pˆi)} and TˆWL = T{θˆWL, FˆWL(pˆi)}, respec-
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tively. For ML, we perform the following decomposition,
√
N
[
T{θˆML, FˆML(θˆML)} − T (θ, F )
]
=
√
N
[
T{θˆML, FˆML(θˆML)} − T{θ, FˆML(θˆML)}
]
+
√
N
[
T{θ, FˆML(θˆML)} − T{θ, FˆML(θ)}
]
+
√
N
[
T{θ, FˆML(θ)} − T (θ, F )
]
.
Apply the first-order Taylor series expansion, we obtain
√
N
[
T{θˆML, FˆML(θˆML)} − T (θ, F )
]
=
{
∂T
∂θ
|F=FˆML(θˆML) +
∂T
∂FˆML(θ)
∂FˆML(θ)
∂θ
}√
N(θˆML − θ)
+
[
T{θ, FˆML(θ)} − T (θ, F )
]
+ op(1).
We obtain similar expressions for PL and WL as
√
N
[
T{θˆPL, FˆPL(θˆPL, pˆi)} − T (θ, F )
]
=
{
∂T
∂θ
|F=FˆPL(θˆPL,pˆi) +
∂T
∂FˆPL(θ,pi)
∂FˆPL(θ,pi)
∂θ
}√
N(θˆPL − θ)
+
∂T
∂pi
√
N(pˆi − pi) +
[
T{θ, FˆPL(θ,pi)} − T (θ, F )
]
+ op(1)
and
√
N
[
T{θˆWL, FˆWL(pˆi)} − T (θ, F )
]
=
∂T
∂θ
√
N(θˆWL − θ) + ∂T
∂pi
√
N(pˆi − pi)
+
[
T{θ, FˆWL(pi)} − T (θ, F )
]
+ op(1).
All three methods share the components of θˆ − θ and T (Fˆ ) − T (F ), while PL and WL have an
additional term of pˆi − pi. The contribution to the influence function of Tˆ by each component is
derived as below.
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Asymptotic Properties of pˆi
We know that
pˆiys =
nys
Nys
=
∑1
y=0
∑S
s=1
∑Nys
k=1 I{Yk = y, Sk = s} ×Rysk∑1
y=0
∑S
s=1
∑Nys
k=1 I{Yk = y, Sk = s}
,
where I{Yk = y, Sk = s} is the indicator of whether the kth subject with Y = y is in the stratum
S = s. Then we derive the influence function Hpiysk by expanding pˆiys − piys as
pˆiys − piys = 1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
Hpiysk,
where Hpiysk =
 1N
1∑
y=0
S∑
s=1
Nys∑
k=1
I{Yk = y, Sk = s}

−1
× I{Yk = y, Sk = s}(Rysk − piys).
Asymptotic Properties of θˆ
Maximum Likelihood Method
We refer readers to Scott and Wild (1997) for the detailed derivation of the profile likelihood function.
Given that ηˆxzs, µys, and γys, as respectively defined in the main paper, are all functions of θ, we
are able to derive the profile likelihood score function by taking the first derivative of the profile
log-likelihood function as
Sp(θ) =
∂lp(θ)
∂θ
=
1∑
y=0
S∑
s=1
Nys∑
k=1
Spysk(θ),
where
Spysk(θ) = (1−Rysk)
∫
x
∫
z
∂
∂θ{py(x, z;θ)ηxzs}dxdz∫
x
∫
z
py(x, z;θ)ηxzsdxdz
+Rysk
{
∂py(xysk,zysk;θ)
∂θ
py(xysk, zysk;θ)
+
∂ηxyskzysks
∂θ
ηxyskzysks
}
,
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and
∂ηxzs
∂θ
=
n+xzs
N+s
−1{∑
y µyspy(x, z;θ)
}2 ∑
y
{
py(x, z;θ)
∂µys
∂θ
+ µys
∂py(x, z;θ)
∂θ
}
,
∂µys
∂θ
=
∂µys
∂γys
∂γys
∂θ
,
∂γ1s
∂θ
= − Bs
1− a+sWs ,with Bs =
∑
(x,z)⊂s
∂p1(x, z;θ)
∂θ
, ays =
1
nys − γys −
1
Nys − γys ,
Ws =
∑
(x,z)⊂s
[
diag{p1(x, z;θ)} − p1(x, z;θ)p1(x, z;θ)T
]
,
∂p1(x, z;θ)
∂θ
= (1,x, z)p1(x, z;θ)p0(x, z;θ).
Then, the influence function can be derived as
θˆML − θ = 1
N
1∑
y=0
S∑
s=1
Nys∑
k=1
HMLθysk + op(1),
where HMLθysk =
{
− 1
N
∂Sp(θ)
∂θ
}−1
Spysk(θ).
Pseudo-Likelihood Method
The PL estimator θˆPL is obtained by fitting the standard logistic regression model to Phase II
subjects with an offset term log(pˆi1s/pˆi0s). Then, we can rewrite the pseudo-model as
p?y(x, z;θ, pˆis) =
exp
[
y{log(pˆi1s)− log(pˆi0s) + α+ βTx + γT z}
]
1 + exp{log(pˆi1s)− log(pˆi0s) + α+ βTx + γT z}
,
where θ = (α,β,γ), pˆis = (pˆi0s, pˆi1s). Then, θˆPL solves the following pseudo-score function
S?(θˆPL, pˆi) =
1∑
y=0
S∑
s=1
Nys∑
k=1
S?ysk(θˆPL, pˆis) =
1∑
y=0
S∑
s=1
Nys∑
k=1
Rysk
∂ log p?y(xysk, zysk; θˆPL, pˆis)
∂θ
= 0.
After the first-order Taylor series expansion
0 = S?(θˆPL, pˆi) = S
?(θ,pi) +
∂S?(θ,pi)
∂θ
(θˆPL − θ) + ∂S
?(θ,pi)
∂pi
(pˆi − pi) + op(1),
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we obtain
θˆPL − θ =
{
− 1
N
∂S?(θ,pi)
∂θ
}−1
1
N
{
S?(θ,pi) +
∂S?(θ,pi)
∂pi
(pˆi − pi)
}
+ op(1)
=
{
− 1
N
∂S?(θ,pi)
∂θ
}−1
1
N

1∑
y=0
S∑
s=1
Nys∑
k=1
S?ysk(θ,pis)−
{
− 1
N
∂S?(θ,pi)
∂pis
}
Hpiysk
+ op(1),
where
∂S?(θ,pi)
∂θ
= −
1∑
y=1
S∑
s=1
Nys∑
k=1
Rysk(1,xysk, zysk)(1,xysk, zysk)
T p?1(xysk, zysk;θ,pis)p
?
0(xysk, zysk;θ,pis)
∂S?(θ,pi)
∂pi0s
=
∑1
y=0
∑Nys
k=1Rysk(1,xysk, zysk)p
?
1(xysk, zysk;θ,pis)p
?
0(xysk, zysk;θ,pis)
pi0s
,
∂S?(θ,pi)
∂pi1s
= −
∑1
y=0
∑Nys
k=1Rysk(1,xysk, zysk)p
?
1(xysk, zysk;θ,pis)p
?
0(xysk, zysk;θ,pis)
pi1s
.
The matrices−N−1∂S?(θ,pi)/∂θ and−N−1∂S?(θ,pi)/∂pis can be shown to converge to a constant
matrix by the law of large numbers. Therefore, we are able to write
θˆPL − θ = 1
N
1∑
y=0
S∑
s=1
N∑
k=1
HPLθysk + op(1),
where HPLθysk =
{
− 1
N
∂S?(θ,pi)
∂θ
}−1 [
S?ysk(θ,pis)−
{
− 1
N
∂S?(θ,pi)
∂pis
}
Hpiysk
]
.
Weighted Likelihood Method
The inference procedures are identical to those for PL. Using the weighted score function instead,
the following quantities will be updated accordingly:
∂SWL(θ,pi)
∂θ
= −
1∑
y=1
S∑
s=1
Nys∑
k=1
Rysk
piys
(1,xysk, zysk)(1,xysk, zysk)
T p1(xysk, zysk;θ)p0(xysk, zysk;θ),
∂SWL(θ,pi)
∂pi0s
=
∑1
y=0
∑Nys
k=1Rysk(1,xysk, zysk){0− p1(xysk, zysk;θ)}
−pi20s
,
∂SWL(θ,pi)
∂pi1s
= −
∑1
y=0
∑Nys
k=1Rysk(1,xysk, zysk){1− p1(xysk, zysk;θ)}
−pi21s
.
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Asymptotic Properties of T (Fˆ )
Let δx,z be the point mass at (x, z). Applying theory for deriving the influence function for the
statistical functionals, we obtain
√
N{T (Fˆ )− T (F )} = T˙{F ;
√
N(Fˆ − F )}+ op(1)
=
√
N
{
1
N
N∑
k=1
ϕF (Xk,Zk)
}
+ op(1),
where ϕF (Xk,Zk) is the influence curve of T at F and is calculated as
lim
→0
T{(1− )F + δx,z} − T (F )

.
Let A(x, z) and B(x, z) denote I{p1(x, z;θ) > ν} and p1(x, z;θ), respectively. The detailed deriva-
tions of ϕF (X,Z) for TPRν and FPRν are given below as
ϕTPRF (x, z) = lim
→0
∫
x,z
A(x,z)B(x,z)d{(1−)F (x,z)+δx,z}∫
x,z
B(x,z)d{(1−)F (x,z)+δx,z} −
∫
x,z
A(x,z)B(x,z)dF (x,z)∫
x,z
B(x,z)dF (x,z)

= lim
→0
(1−) ∫
x,z
A(x,z)B(x,z)dF (x,z)+
∫
x,z
A(x,z)B(x,z)dδx,z
(1−) ∫
x,z
B(x,z)dF (x,z)+
∫
x,z
B(x,z)dδx,z
−
∫
x,z
A(x,z)B(x,z)dF (x,z)∫
x,z
B(x,z)dF (x,z)

= lim
→0
(1−) ∫
x,z
A(x,z)B(x,z)dF (x,z)+A(x,z)B(x,z)
(1−) ∫
x,z
B(x,z)dF (x,z)+B(x,z)
−
∫
x,z
A(x,z)B(x,z)dF (x,z)∫
x,z
B(x,z)dF (x,z)

= lim
→0
A(x, z)B(x, z)
∫
x,z
B(x, z)dF (x, z)−B(x, z) ∫
x,z
A(x, z)B(x, z)dF (x, z){
(1− ) ∫
x,z
B(x, z)dF (x, z) + B(x, z)
}
× ∫
x,z
B(x, z)dF (x, z)
=
A(x, z)B(x, z)
∫
x,z
B(x, z)dF (x, z)−B(x, z) ∫
x,z
A(x, z)B(x, z)dF (x, z){∫
x,z
B(x, z)dF (x, z)
}2
=
B(x, z) {A(x, z)− TPR}∫
x,z
B(x, z)dF (x, z)
=
p1(x, z;θ) [I{p1(x, z;θ) > ν} − TPR]
Ex,z{p1(x, z;θ)} .
Similarly, we can derive the influence function for FPRν by simply replacing p1(x, z;θ) with 1 −
p1(x, z;θ):
ϕFPRF (x, z) =
{1− p1(x, z;θ)} [I{p1(x, z;θ) > ν} − FPR]
Ex,z[{1− p1(x, z;θ)}] .
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The influence function for AUC is derived accordingly as
ϕAUCF (x, z) =
∫
TPRνdϕFPRF (x, z) +
∫
ϕTPRF (x, z)dFPRν .
The influence functions for PCFq and PNFp can be derived following the same line as Pfeiffer and
Gail, 2011 (equation (10) and (12)).
Asymptotic Properties of T
{
θˆPL, FˆPL(θˆPL, pˆi)
}
Under the PL method, we write TˆPL ≡ T
{
θˆPL, FˆPL(θˆPL, pˆi)
}
as the generic notation for all three
measures. By applying the standard Taylor series expansion and Delta method for statistical func-
tionals, we obtain the following asymptotic linear approximations with details provided above:
√
N(θˆPL − θ) =
√
N
{
1
N
N∑
k=1
HPLθk
}
+ op(1),
√
N{T (θ, FˆPL)− T (θ, F )} =
√
N
{
1
N
N∑
k=1
ϕPLF (Xk,Zk)
}
+ op(1),
√
N(pˆi − pi) =
√
N
{
1
N
N∑
k=1
Hpik
}
+ op(1).
Then the asymptotic linear approximation of TˆPL can be obtained as
√
N(TˆPL − T ) =
√
N
{
1
N
N∑
k=1
HPLTk
}
+ op(1),
where HPLTk is calculated as
HPLTk =
{
∂T
∂θ
|F=FˆPL(θˆPL,pˆi) +
∂T
∂FˆPL(θ,pi)
∂FˆPL(θ,pi)
∂θ
}
HPLθk +
∂T
∂pi
Hpik + ϕ
PL
F (Xk,Zk).
Asymptotic Properties of T{θˆWL, FˆWL(pˆi)}
Now write TˆWL ≡ T{θˆWL, FˆWL(pˆi)} as the generic notation for the three predictive accuracy mea-
sures. We obtain its asymptotic linear approximation as
√
N(TˆWL − T ) =
√
N
{
1
N
∑N
k=1H
WL
Tk
}
+
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op(1), where the influence function HWLTk takes the form
HWLTk =
∂T
∂θ
HWLθk +
∂T
∂pi
Hpik + ϕ
WL
F (Xk,Zk).
The terms HWLθk , Hpik, and ϕ
WL
F (Xk,Zk) are defined similar to those of the PL approach above
(Supplementary Material). Then TˆWL is asymptotically normally distributed, and the asymptotic
variance-covariance matrix can be estimated as N−2
∑N
k=1H
WL
Tk (H
WL
Tk )
T .
A.2. Chapter 3
A.2.1. Derivation of the profile likelihood
Given
g∗(α,β, τ ,pi,λ,λ∗) = l(α,β, τ ,pi) +
M∑
s=1
λ∗s
{
K∑
k=1
pisk − 1
}
+
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}
,
we notice that the second constraint doesn’t involve pi, therefore we focus on the first two terms of
g∗(α,β, τ ,pi,λ,λ∗). By differentiating with respect to pi, we obtain the following
∂g∗
∂pisk
=
n+sk+
pisk
−
1∑
i=0
nis++
∑L
l=1 Pisklfτ (zl|s,xk)∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
+ λ∗s = 0.
Multiplying pisk by both sides of the equation and summing over k, we obtain
K∑
k=1
n+sk+ −
K∑
k=1
pisk
1∑
i=0
nis++
∑L
l=1 Pisklfτ (zl|s,xk)∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
+ λ∗s
K∑
k=1
pisk = 0,
n+s++ −
1∑
i=0
nis++
K∑
k=1
pisk
∑L
l=1 Pisklfτ (zl|s,xk)∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
+ λ∗s = 0,
n+s++ −
1∑
i=0
nis++
K∑
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
+ λ∗s = 0,
n+s++ −
1∑
i=0
nis++ + λ
∗
s = 0,
λ∗s = 0.
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Therefore, we are able to express pisk as a function of (αs,β, τ , µis):
pˆisk(αs,β, τ , µis) =
n+sk+
n+s++
∑1
i=0 µis
∑L
l=1 Pisklfτ (zl|s,xk)
,
where µis =
nis++
n+s++
∑K
k=1
∑L
l=1 Pisklpiskfτ (zl|s,xk)
.
Plugging λ∗ = 0 and pˆisk back into g∗(α,β, τ ,pi,λ,λ∗) then gives the profile likelihood equivalent
to (3.4).
A.2.2. The Score Function and Negative Information Matrix for Constrained Maximum Likelihood
Method
Given the constrained profile likelihood function g(α,β, τ ,µ,λ) (equation (4) in the main text),
we can calculate the corresponding score functions for (α,β, τ ,µ,λ), respectively. After we re-
parametrize µs = log µ1sµ0s , s = 1, ...,M , we obtain the score functions as
Sαs =
1∑
i=0
K∑
k=1
L∑
l=1
niskl(i− P1skl)− (eµs − 1)
K∑
k=1
n+sk+
∑L
l=1 P1sklP0sklfτ (zl|s,xk)∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
+
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Sβ =
1∑
i=0
M∑
s=1
K∑
k=1
L∑
l=1
niskl(xk, zl)(i− P1skl)
−
M∑
s=1
K∑
k=1
(eµs − 1)n+sk+
∑L
l=1(xk, zl)P1sklP0sklfτ (zl|s,xk)∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
+
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1(xk, zl)P1sklP0sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Sτ =
M∑
s=1
K∑
k=1
L∑
l=1
n+skl
∂fτ (zl|s,xk)/∂τ
fτ (zl|s,xk) −
M∑
s=1
K∑
k=1
n+sk+
∑L
l=1(e
µsP1skl + P0skl)∂fτ (zl|s,xk)/∂τ∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
+
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδsk∂fτ (zl|s,xk)/∂τ∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Sµs =
1∑
i=0
K∑
k=1
L∑
l=1
niskl
{
i− e
µs
∑L
l=1 P1sklfτ (zl|s,xk)∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}
,
Sλsr =
∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
,
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where s = 1, ...,M, r = 1, ..., Is. The component matrices for
I = − ∂
2g(α,β, τ ,µ,λ)
∂(α,β, τ ,µ,λ)∂(α,β, τ ,µ,λ)T
are calculated as
Iαsαs = −
∂Sαs
∂αs
=
K∑
k=1
L∑
l=1
n+sklP1sklP0skl − (eµs − 1)
K∑
k=1
n+sk+
∑L
l=1 P1sklP0skl(P1skl − P0skl)fτ (zl|s,xk)∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
− (eµs − 1)
K∑
k=1
n+sk+
{∑L
l=1 P1sklP0sklfτ (zl|s,xk)
}2
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
+
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0skl(P1skl − P0skl)δskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Iββ = −∂Sβ
∂β
=
M∑
s=1
K∑
k=1
L∑
l=1
n+sklP1sklP0skl(xk, zl)
T (xk, zl)
−
M∑
s=1
(eµs − 1)
K∑
k=1
n+sk+
∑L
l=1 P1sklP0skl(P1skl − P0skl)fτ (zl|s,xk)(xk, zl)T (xk, zl)∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
−
M∑
s=1
K∑
k=1
(eµs − 1)n+sk+
{∑L
l=1 P1sklP0sklfτ (zl|s,xk)(xk, zl)
}T {∑L
l=1 P1sklP0sklfτ (zl|s,xk)(xk, zl)
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
+
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0skl(P1skl − P0skl)δskfτ (zl|s,xk)(xk, zl)T (xk, zl)∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Iττ = −∂Sτ
∂τ
= −
M∑
s=1
K∑
k=1
L∑
l=1
n+skl
∂2fτ (zl|s,xk)/∂τ∂τT
fτ (zl|s,xk) +
M∑
s=1
K∑
k=1
L∑
l=1
n+skl
{
∂fτ (zl|s,xk)
∂τ
}T {
∂fτ (zl|s,xk)
∂τ
}
f2τ (zl|s,xk)
+
M∑
s=1
K∑
k=1
n+sk+
∑L
l=1(e
µsP1skl + P0skl)∂
2fτ (zl|s,xk)/∂τ∂τT∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
−
M∑
s=1
K∑
k=1
n+sk+
{∑L
l=1(e
µsP1skl + P0skl)
∂fτ (zl|s,xk)
∂τ
}T {∑L
l=1(e
µsP1skl + P0skl)
∂fτ (zl|s,xk)
∂τ
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
−
M∑
s=1
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδsk∂
2fτ (zl|s,xk)/∂τ∂τT∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
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and
Iµsµs = −
∂Sµs
∂µs
=
K∑
k=1
L∑
l=1
n+skl
{
eµs
∑L
l=1 P1sklfτ (zl|s,xk)
}{∑L
l=1 P0sklfτ (zl|s,xk)
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
Iαsτ = Iταs = −
Sαs
∂τ
= (eµs − 1)
K∑
k=1
n+sk+
∑L
l=1 P1sklP0skl
∂fτ (zl|s,xk)
∂τ∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
− (eµs − 1)
K∑
k=1
n+sk+
{∑L
l=1 P1sklP0sklfτ (zl|s,xk)
}{∑L
l=1(e
µsP1skl + P0skl)
∂fτ (zl|s,xk)
∂τ
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
−
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0sklδsk
∂fτ (zl|s,xk)
∂τ∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Iβτ = Iτβ = −Sβ
∂τ
=
M∑
s=1
(eµs − 1)
K∑
k=1
n+sk+
∑L
l=1 P1sklP0skl(xk, zl)
∂fτ (zl|s,xk)
∂τ∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
−
M∑
s=1
K∑
k=1
(eµs − 1)n+sk+
{∑L
l=1 P1sklP0skl(xk, zl)fτ (zl|s,xk)
}{∑L
l=1(e
µsP1skl + P0skl)
∂fτ (zl|s,xk)
∂τ
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
−
Is∑
r=1
λsr
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0sklδsk(xk, zl)
∂fτ (zl|s,xk)
∂τ∑
k:asr≤ϕ(s,xk)≤bsr δsk
}
,
Iαsµs = Iµsαs = −
∂Sαs
∂µs
=
K∑
k=1
n+sk+
eµs
∑L
l=1 P1sklP0sklfτ (zl|s,xk){∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2 ,
Iβµs = Iµsβ = −
∂Sβ
∂µs
=
M∑
s=1
K∑
k=1
n+sk+
eµs
∑L
l=1 P1sklP0sklfτ (zl|s,xk)(xk, zl){∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2 ,
I(αs,β)λsr = Iλsr(αs,β) = −
∂Sλsr
∂(αs,β)
=
∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklP0sklδskfτ (zl|s,xk)(1,xk, zl)∑
k:asr≤ϕ(s,xk)≤bsr δsk
79
and
Iτµs = Iµsτ = −
∂Sτ
∂µs
=
K∑
k=1
n+sk+
eµs
{∑L
l=1 P1skl
∂fτ (zl|s,xk)
∂τ
}{∑L
l=1 P0sklfτ (zl|s,xk)
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2
−
K∑
k=1
n+sk+
eµs
{∑L
l=1 P0skl
∂fτ (zl|s,xk)
∂τ
}{∑L
l=1 P1sklfτ (zl|s,xk)
}
{∑L
l=1(e
µsP1skl + P0skl)fτ (zl|s,xk)
}2 ,
Iτλsr = Iλsrτ = −
∂Sλsr
∂τ
= −
∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδsk∂fτ (zl|s,xk)/∂τ∑
k:asr≤ϕ(s,xk)≤bsr δsk
.
The matrices of Iλ and Iλµ = Iµλ are zero.
A.2.3. Proofs of the Identifiability and Consistency
Correct model
Assume the model in (3.1) is correct. The identifiability of the parameters α,β, τ ,pi has been
shown in the literature. We now show that using the constrained ML approach above, the maximizer
converges to the true parameter values. Proof:
Consider maximizing
Mn,c(θ) ≡ n−1l(α,β, τ ,pi)− c2
M∑
s=1
(
K∑
k=1
pisk − 1)2
− c2
M∑
s=1
Is∑
r=1
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
with respect to θ, where θ = (αT ,βT , τT ,piT )T . For simplicity, we assume the parameter space Θ
is bounded. Define
Mc(θ) = E{n−1l(α,β, τ ,pi)} − c2
M∑
s=1
(
K∑
k=1
pisk − 1)2
− c2
M∑
s=1
Is∑
r=1
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
.
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It is easy to see that supθ∈Θ |Mn,c(θ) −Mc(θ)| → 0 in probability. Let θ0 be the true parameter.
Furthermore, based on the maximum likelihood property and the uniqueness of the true parameter
values following from the identifiability, it is clear that for any θ such that ‖θ − θ0‖ >  > 0,
Mc(θ) = E{n−1l(α,β, τ ,pi)} − c2
M∑
s=1
(
K∑
k=1
pisk − 1)2
− c2
M∑
s=1
Is∑
r=1
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
≤ E{n−1l(θ)}
=
∫
log{f(X,Z, S, Y,θ)}f(X,Z, S, Y,θ0)dµ(x, z, s, y)
=
∫
log{f(X,Z, S, Y,θ)/f(X,Z, S, Y,θ0)}f(X,Z, S, Y,θ0)dµ(x, z, s, y)
+
∫
log f(X,Z, S, Y,θ0)f(X,Z, S, Y,θ0)dµ(x, z, s, y)
<
∫
{f(X,Z, S, Y,θ)/f(X,Z, S, Y,θ0)− 1}f(X,Z, S, Y,θ0, )dµ(x, z, s, y)
+ E{log f(X,Z, S, Y,θ0)}
= E{n−1l(θ0)}
= E{n−1l(θ0)} − c2
M∑
s=1
(
K∑
k=1
pisk0 − 1)2
− c2
M∑
s=1
Is∑
r=1
{
P e(Y = 1, asr ≤ ϕ(s,x) ≤ bsr)
P e(asr ≤ ϕ(s,x) ≤ bsr) − P
e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
=Mc(θ0),
where we used log(t) < t − 1 for t 6= 1 and t > 0. Thus, following Theorem 5.7 of Van der Vaart
(1998), the maximizer of Mn,c(θ) converges to the unique true parameter θ0 in probability. When
c → ∞, the maximizer of Mn,c(θ) can be made arbitrarily close to the constrained MLE θ̂. Thus,
the constrained MLE θ̂ converges to the unique true parameter θ0 in probability.
Arbitrary model
Without assuming the model in (3.1) is correctly specified, the identifiability needs to be established
first. Here, by identifiability, we mean that there are no two sets of parameters α,β, τ ,pi and
α˜, β˜, τ˜ , p˜i so that they both satisfy the constraints in (3.2) and (3.3), and P (x, z|y, s,α,β, τ ,pi) =
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P (x, z|y, s, α˜, β˜, τ˜ , p˜i) for all (x, z, y, s) combinations.
Proof: We assume that there exist α,β, τ ,pi and α˜, β˜, τ˜ , p˜i so that
exp{i(αs + βTxxk + βTz zl)}
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
/
{
K∑
k=1
L∑
l=1
exp{i(αs + βTxxk + βTz zl)}
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
}
=
exp{i(α˜s + β˜
T
xxk + β˜
T
z zl)}
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
piskfτ˜ (zl|s,xk)
/
{
K∑
k=1
L∑
l=1
exp{i(α˜s + β˜
T
xxk + β˜
T
z zl)}
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
piskfτ˜ (zl|s,xk)
}
(A.1)
for all i = 0, 1, k = 1, . . . ,K, l = 1, . . . , L and s = 1, . . . , S. This leads to
exp{i(βTxxk + βTz zl)}
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
/
{
K∑
k=1
L∑
l=1
exp{i(βTxxk + βTz zl)}
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
}
=
exp{i(β˜Txxk + β˜
T
z zl)}
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
piskfτ˜ (zl|s,xk)
/
{
K∑
k=1
L∑
l=1
exp{i(β˜Txxk + β˜
T
z zl)}
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
piskfτ˜ (zl|s,xk)
}
for all i = 0, 1, k = 1, . . . ,K, l = 1, . . . , L and s = 1, . . . , S. Taking ratio of the value at i = 1 and
i = 0 on each side, we get
exp(βTxxk + β
T
z zl)
{
K∑
k=1
L∑
l=1
piskfτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
}
/
{
K∑
k=1
L∑
l=1
exp(βTxxk + β
T
z zl)
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
}
= exp(β˜
T
xxk + β˜
T
z zl)
{
K∑
k=1
L∑
l=1
piskfτ˜ (zl|s,xk)
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
}
/
{
K∑
k=1
L∑
l=1
exp(β˜
T
xxk + β˜
T
z zl)
1 + exp(α˜s + β˜
T
xxk + β˜
T
z zl)
piskfτ˜ (zl|s,xk)
}
for all k = 1, . . . ,K, l = 1, . . . , L and s = 1, . . . , S. Note that on both sides, other than the first
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exponential term, the remaining quantities are not functions of x, z, hence we actually get exp(βTxx+
βTz z) = c exp(β˜
T
xx + β˜
T
z z) for some c that does not depend on x, z. Thus, βx = β˜x,βz = β˜z and
c = 1. Thus, letting i = 0 and i = 1 respectively, (A.1) further leads to
piskfτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
/
{
K∑
k=1
L∑
l=1
piskfτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
}
=
piskfτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
/
{
K∑
k=1
L∑
l=1
piskfτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
}
(A.2)
and
pisk exp(αs + β
T
xxk + β
T
z zl)fτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
/
{
K∑
k=1
L∑
l=1
exp(αs + β
T
xxk + β
T
z zl)
1 + exp(αs + β
T
xxk + β
T
z zl)
piskfτ (zl|s,xk)
}
=
pisk exp(α˜s + β
T
xxk + β
T
z zl)fτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
/
{
K∑
k=1
L∑
l=1
exp(α˜s + β
T
xxk + β
T
z zl)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
piskfτ˜ (zl|s,xk)
}
(A.3)
for all k = 1, . . . ,K, l = 1, . . . , L and s = 1, . . . , S.
Now assume that for any (s, k), we can select a suitable interval [asr, bsr] so that ϕ(s, xk) is the
only ϕ value in the interval. I need the above assumption. This essentially says the different
combinations of (s, k) are distinguishable in the external study. I guess this assumption is okay?
Then (3.3) yields P e(Y = 1|s,xk) =
∑L
l=1 P1sklfτ (zl|s,xk). This also implies P e(Y = 0|s,xk) =∑L
l=1 P0sklfτ (zl|s,xk). Plugging this into (A.2) and (A.3), we get
piskfτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
/{
K∑
k=1
piskP
e(Y = 0|s,xk)}
=
piskfτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
/{
K∑
k=1
piskP
e(Y = 0|s,xk)}
and
pisk exp(αs + β
T
xxk + β
T
z zl)fτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
/{
K∑
k=1
piskP
e(Y = 1|s,xk)}
=
pisk exp(α˜s + β
T
xxk + β
T
z zl)fτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
/{
K∑
k=1
piskP
e(Y = 1|s,xk)} (A.4)
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Summing the above for l = 1 to L, we further get
piskP
e(Y = 0|s,xk)∑K
k=1 piskP
e(Y = 0|s,xk)
=
piskP
e(Y = 0|s,xk)∑K
k=1 piskP
e(Y = 0|s,xk)
piskP
e(Y = 1|s,xk)∑K
k=1 piskP
e(Y = 1|s,xk)
=
piskP
e(Y = 1|s,xk)∑K
k=1 piskP
e(Y = 1|s,xk)
.
Adding the above two equalities, we get pisk = piskcs for some constant cs at each s. Since∑K
k=1 pisk =
∑K
k=1 pisk = 1, this implies cs = 1 and pisk = pisk. Using this relation in (A.4) we
get
fτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
=
fτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
exp(αs + β
T
xxk + β
T
z zl)fτ (zl|s,xk)
1 + exp(αs + β
T
xxk + β
T
z zl)
=
exp(α˜s + β
T
xxk + β
T
z zl)fτ˜ (zl|s,xk)
1 + exp(α˜s + β
T
xxk + β
T
z zl)
,
which leads to fτ (zl | s,xk) = fτ˜ (zl | s,xk), hence τ = τ˜ . This further leads to αs = α˜s. Thus, the
problem is indeed identifiable.
Consistency of the constrained MLE.
Proof:
Let θ = (αT ,βT , τT ,piT )T . We define
Mn,c(θ) ≡ n−1l(α,β, τ ,pi)− c2
M∑
s=1
(
K∑
k=1
pisk − 1)2
− c2
M∑
s=1
Is∑
r=1
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
,
Mc(θ) ≡ E{n−1l(α,β, τ ,pi)} − c2
M∑
s=1
(
K∑
k=1
pisk − 1)2
− c2
M∑
s=1
Is∑
r=1
{∑
k:asr≤ϕ(s,xk)≤bsr
∑L
l=1 P1sklδskfτ (zl|s,xk)∑
k:asr≤ϕ(s,xk)≤bsr δsk
− P e(Y = 1|asr ≤ ϕ(s,x) ≤ bsr)
}2
.
Let a maximizer of Mn,c(θ) be θ̂n,c and a maximizer of Mc(θ) be θ0,c. We assume θ0,c is unique for
sufficiently large c. Further, we define θ̂n to be a solution of the constrained maximization problem.
It is easy to see that supθ∈Θ |Mn(θ)−M(θ)| → 0 in probability. Further, the definition of θ0,c yields
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that for any θ such that ‖θ − θ0,c‖ >  > 0,
M(θ) < M(θ0,c).
Thus, following Theorem 5.7 of Van der Vaart (1998), the maximizer of Mn,c(θ), θ̂n,c converges
to the unique maximizer θ0,c in probability. Now since Θ is bounded, it is not stringent to assume
that n−1l(α,β, τ ,pi) and E{n−1l(α,β, τ ,pi)} are bounded in Θ. Thus, when c → ∞, we have
θ̂n,c → θ̂n and θ0,c → θ0, where θ̂n is the solution of the constrainted maximization problem and
θ0 is the parameter that yields the minimum Kullback-Leibler distance to the true density among all
the parameters that satisfy the constraints in both (3.2) and (3.3). These results combined together
yield θ̂n → θ0 in probability.
A.3. Chapter 4
A.3.1. The Score Function and Negative Information Matrix for Constrained Maximum Likelihood
Method
Given the constrained likelihood function g(α,β, τ ,λ) (equation (3) in the main text), we can calcu-
late the corresponding score functions for (α,β, τ ,λ), respectively. Let Pyxz ≡ P (Y = y|x, z), y =
0, 1. The expressions are given as below:
S(α,β) =
N∑
i=1
(1,xi, zi)(yi − P1xizi) +
I∑
r=1
λr
{∫
x:ar≤ϕ(x)≤br
∫
z
(1,x, z)P1xzP0xzP
e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
}
,
Sτ =
N∑
i=1
∂fτ (zi|xi)/∂τ
fτ (zi|xi) +
I∑
r=1
λr
{∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)∂fτ (zl|s,xk)/∂τdzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
}
,
Sλr =
∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
− P e(Y = 1|ar ≤ ϕ(x) ≤ br), r = 1, ..., I.
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The component matrices for I = −∂2g(α,β, τ ,λ)/∂(αT ,βT , τT ,λT )T∂(αT ,βT , τT ,λT ) are calcu-
lated as
I(α,β)(α,β) = − ∂
2g(α,β, τ ,λ)
∂(α,β)∂(α,β)T
=
N∑
i=1
P1xiziP0xizi(1,xi, zi)
T (1,xi, zi)
+
I∑
r=1
λr
{∫
x:ar≤ϕ(x)≤br
∫
z
(1,x, z)T (1,x, z)P1xzP0xz(P1xz − P0xz)P e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
}
,
Iττ = −∂
2g(α,β, τ ,λ)
∂τ∂τT
=
N∑
i=1
{
∂fτ (zi|xi)
∂τ
∂fτ (zi|xi)
∂τT
f2τ (zi|xi)
− ∂
2fτ (zi|xi)/∂τ∂τT
fτ (zi|xi)
}
+
I∑
r=1
λr
{∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)∂f2τ (z|x)/∂τ∂τT dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
}
,
Iλλ = −∂
2g(α,β, τ ,λ)
∂λ∂λT
= 0
and
I(α,β)τ = I
T
τ (α,β) = −
∂2g(α,β, τ ,λ)
∂(α,β)∂τ
= −
∫
x:ar≤ϕ(x)≤br
∫
z
(1,x, z)P1xzP0xzP
e(x)∂fτ (z|x)/∂τdzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
,
I(α,β)λr = I
T
λr(α,β)
= −∂
2g(α,β, τ ,λ)
∂(α,β)∂λr
=
∫
x:ar≤ϕ(x)≤br
∫
z
(1,x, z)P1xzP0xzP
e(x)fτ (z|x)dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
,
Iτλr = I
T
λrτ = −
∂2g(α,β, τ ,λ)
∂τ∂λr
=
∫
x:ar≤ϕ(x)≤br
∫
z
P1xzP
e(x)∂f2τ (zl|s,xk)/∂τ∂τT dzdx∫
x:ar≤ϕ(x)≤br P
e(x)dx
.
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APPENDIX B
SOFTWARE
B.1. Chapter 2: Software Package for Implementing the Proposed Methods
We developed an R package “TwoPhaseAccuracy” that implemented the three approaches de-
scribed in Chapter 2, which is freely available and easy for users to install. In this package, function
“evalTwoPhase” is for calculating AUC, PCF, and PNF using all the three approaches, and function
“seTwoPhase” is for estimating the corresponding standard errors using bootstrap resampling. The
input arguments of the two functions include the estimation method (“MLE”, “PL” or “WL”), threshold
values for estimating PCF and PNF, and data that contains case-control status, stratum member-
ship, Phase I predictors, Phase II predictors, variable names, and a variable indicating whether a
subject was selected into Phase II. Function “seTwoPhase” includes an additional input argument
for the number of bootstrap samples. A third function, “summaryTwoPhase”, summarizes the re-
sults from “evalTwoPhase” and “seTwoPhase” by outputing the estimates of AUC, PCF, and PNF
together with their standard error estimates.
B.2. Chapter 3
B.2.1. Additional BCDDP Analysis
Table B.1 presents further analysis of BCDDP. In this analysis, we put different constraints on the
prediction model with finer constraints on the tails of the risk distribution while cruder in the middle
50%. In contrast to the quartiles used in the main text, we chose (25%, 75%) percentiles of the
BCRAT risk as cutoff points for stratum 1 (age ≤ 50) and (15%, 25%, 75%, 85%) percentiles for
stratum 2 (age > 50).
B.2.2. P e(X|S) Estimated from the National Health Interview Surve (NHIS)
Table B.2 and Table B.3 respectively displays the joint probability distribution of (Ageflb, Agemen,
Weight) and (Nbiops, Numrel) given age ≤ 50 or age > 50. Then, P e(X|S) can be calculated as
the product of the two by assuming their independence of each other.
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Table B.1: Analysis of the BCDDP data with BCRAT risk cutoffs placed at the (25%, 75%) for
stratum 1 and (15%, 25%, 75%, 80%) for stratum 2: estimates of stratum-specific intercept terms
and log ORs for the BCRAT predictors, weight, and PD, together with estimates of parameters
in the zero-inflated Beta regression model for the distribution of PD. In the parenthesis are the
corresponding estimates of asymptotic standard errors. “cMLE” represents estimates from the
proposed constrained maximum likelihood method, and “Standard” represents the estimates from
the standard method.
Predictors cMLE Standard
Logistic Regression Model Intercept -6.512 (0.135) -6.751 (0.182)
for Breast Cancer Risk Age≥50 1.198 (0.032) 1.045 (0.035)
Ageflb 0.513 (0.025) 0.105 (0.049)
Agemen 0.217 (0.045) 0.213 (0.061)
Nbiops 0.543 (0.043) 0.174 (0.070)
Numrel 0.485 (0.019) 0.668 (0.090)
Weight -0.199 (0.033) 0.228 (0.044)
PDc 0.174 (0.017) 0.177 (0.018)
The PD distribution Intercept 0.163 (0.073) 0.035 (0.088)
Age≥50 -0.541 (0.049) -0.405 (0.057)
The mean model Ageflb 0.146 (0.027) 0.139 (0.033)
γ Nbiops 0.289 (0.035) 0.248 (0.045)
Weight -0.446 (0.025) -0.421 (0.033)
The variance model Intercept 1.386 (0.097) 1.478 (0.101)
ω Age≥50 0.206 (0.078) 0.202 (0.079)
Weight -0.093 (0.035) -0.121 (0.045)
Mixture probability ρ 0.096 (0.008) 0.105 (0.010)
88
Table B.2: Joint probability distribution of (Ageflb, Agemen Weight): “Before50” represents esti-
mated probability given age ≤ 50; “After50” represents estimated probability given age > 50
Ageflb Agemen Weight Before50 After50
<20 <12 (100, 125] 0.00789 0.00544
20-24 <12 (100, 125] 0.00887 0.00855
25-29 or never <12 (100, 125] 0.00871 0.00796
30+ <12 (100, 125] 0.00207 0.00132
<20 12-13 (100, 125] 0.01471 0.01642
20-24 12-13 (100, 125] 0.02629 0.03377
25-29 or never 12-13 (100, 125] 0.05274 0.02836
30+ 12-13 (100, 125] 0.02071 0.00663
<20 14+ or never (100, 125] 0.01003 0.00739
20-24 14+ or never (100, 125] 0.01574 0.02166
25-29 or never 14+ or never (100, 125] 0.02821 0.02122
30+ 14+ or never (100, 125] 0.01215 0.00549
<20 <12 (125, 150] 0.00744 0.01290
20-24 <12 (125, 150] 0.01015 0.02310
25-29 or never <12 (125, 150] 0.02186 0.01849
30+ <12 (125, 150] 0.00828 0.00266
<20 12-13 (125, 150] 0.03201 0.03899
20-24 12-13 (125, 150] 0.05249 0.08446
25-29 or never 12-13 (125, 150] 0.09420 0.05729
30+ 12-13 (125, 150] 0.03438 0.01446
<20 14+ or never (125, 150] 0.01842 0.02178
20-24 14+ or never (125, 150] 0.02821 0.04803
25-29 or never 14+ or never (125, 150] 0.03977 0.03581
30+ 14+ or never (125, 150] 0.02349 0.00868
<20 <12 (150, 175] 0.00679 0.01182
20-24 <12 (150, 175] 0.01080 0.01831
25-29 or never <12 (150, 175] 0.01503 0.01233
30+ <12 (150, 175] 0.00619 0.00257
<20 12-13 (150, 175] 0.02009 0.03423
20-24 12-13 (150, 175] 0.03376 0.05725
25-29 or never 12-13 (150, 175] 0.04709 0.03544
30+ 12-13 (150, 175] 0.01888 0.01078
<20 14+ or never (150, 175] 0.00540 0.01270
20-24 14+ or never (150, 175] 0.01542 0.03556
25-29 or never 14+ or never (150, 175] 0.01633 0.02253
30+ 14+ or never (150, 175] 0.00780 0.00432
<20 <12 (175, 200] 0.00896 0.00859
20-24 <12 (175, 200] 0.00925 0.00818
25-29 or never <12 (175, 200] 0.01131 0.00871
30+ <12 (175, 200] 0.00354 0.00225
<20 12-13 (175, 200] 0.01544 0.01703
20-24 12-13 (175, 200] 0.01997 0.03626
25-29 or never 12-13 (175, 200] 0.02822 0.01976
30+ 12-13 (175, 200] 0.01113 0.00726
<20 14+ or never (175, 200] 0.00500 0.00829
20-24 14+ or never (175, 200] 0.00606 0.01862
25-29 or never 14+ or never (175, 200] 0.00619 0.00841
30+ 14+ or never (175, 200] 0.00282 0.00327
<20 <12 >200 0.00829 0.00297
20-24 <12 >200 0.00377 0.00283
25-29 or never <12 >200 0.00782 0.00532
30+ <12 >200 0.00139 0.00067
<20 12-13 >200 0.00954 0.00997
20-24 12-13 >200 0.01390 0.01246
25-29 or never 12-13 >200 0.02451 0.01349
30+ 12-13 >200 0.00421 0.00236
<20 14+ or never >200 0.00417 0.00476
20-24 14+ or never >200 0.00765 0.00567
25-29 or never 14+ or never >200 0.00395 0.00317
30+ 14+ or never >200 0.00048 0.00103
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Table B.3: Joint probability distribution of (Nbiops, Numrel): “Before50” represents estimated prob-
ability given age ≤ 50; “After50” represents estimated probability given age > 50
Nbiops Numrel Before50 After50
0 0 0.81122 0.72053
1 0 0.07079 0.10636
2+ 0 0.02231 0.04024
0 1 0.08102 0.09572
1 1 0.00880 0.01532
2+ 1 0.00231 0.00779
0 2+ 0.00354 0.00976
1 2+ 0.00000 0.00207
2+ 2+ 0.00000 0.00219
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